Overview

asciminib

kinase inhibitor

• CYP3A4 substrate
• CYP2C8 inhibitor, weak
• CYP2C9 inhibitor, moderate
• CYP3A4 inhibitor, weak
• BCRP inhibitor
• P-gp inhibitor, weak
• cardiotoxic effects
• hypertensive effects
• immunomodulatory effects
• myelosuppressive oncologic agent
• prolongs QT interval (conditional)
• thrombogenic effects

Contraindicated

• adenovirus vaccine, live
Scemblix (asciminib)

+

adenovirus vaccine, live

1 interaction

Contraindicated

asciminib + adenovirus vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• chikungunya vaccine, live
Scemblix (asciminib)

+

chikungunya vaccine, live

1 interaction

Contraindicated

asciminib + chikungunya vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• cholera vaccine, live
Scemblix (asciminib)

+

cholera vaccine, live

1 interaction

Contraindicated

asciminib + cholera vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• cisapride
Scemblix (asciminib)

+

cisapride

1 interaction

Contraindicated

asciminib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• colchicine
Scemblix (asciminib)

+

colchicine

1 interaction

Contraindicated

asciminib + colchicine

CV RISK REDUCTION: monitor CBC; consider monitoring CK, myopathy s/sx; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or monitor CBC; consider decr. colchicine dose during and x14 days after asciminib use: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• dengue vaccine, live
Scemblix (asciminib)

+

dengue vaccine, live

1 interaction

Contraindicated

asciminib + dengue vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• deuruxolitinib
Scemblix (asciminib)

+

deuruxolitinib

1 interaction

Contraindicated

asciminib + deuruxolitinib

contraindicated: combo may incr. deuruxolitinib levels, risk of serious infection, thromboembolism, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• eliglustat
Scemblix (asciminib)

+

eliglustat

1 interaction

Contraindicated

asciminib + eliglustat

CYP2D6 EM: contraindicated if Child-Pugh Class A and if also combined w/ moderate or strong CYP2D6 inhibitor; if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 IM: if also combined w/ moderate or strong CYP2D6 inhibitor, monitor ECG and decr. eliglustat dose to 84 mg qd; otherwise, monitor ECG; CYP2D6 PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• influenza nasal vaccine, live
Scemblix (asciminib)

+

influenza nasal vaccine, live

1 interaction

Contraindicated

asciminib + influenza nasal vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• measles/mumps/rubella vaccine, live
Scemblix (asciminib)

+

measles/ mumps/ rubella vaccine, live

1 interaction

Contraindicated

asciminib + measles/ mumps/ rubella vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• pimozide
Scemblix (asciminib)

+

pimozide

1 interaction

Contraindicated

asciminib + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• rotavirus vaccine, live
Scemblix (asciminib)

+

rotavirus vaccine, live

1 interaction

Contraindicated

asciminib + rotavirus vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• smallpox vaccine, live
Scemblix (asciminib)

+

smallpox vaccine, live

1 interaction

Contraindicated

asciminib + smallpox vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• thioridazine
Scemblix (asciminib)

+

thioridazine

1 interaction

Contraindicated

asciminib + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• typhoid vaccine, live
Scemblix (asciminib)

+

typhoid vaccine, live

1 interaction

Contraindicated

asciminib + typhoid vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• varicella vaccine, live
Scemblix (asciminib)

+

varicella vaccine, live

1 interaction

Contraindicated

asciminib + varicella vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• yellow fever vaccine, live
Scemblix (asciminib)

+

yellow fever vaccine, live

1 interaction

Contraindicated

asciminib + yellow fever vaccine, live

contraindicated; vaccinate at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Avoid/Use Alternative

• abrocitinib
Scemblix (asciminib)

+

abrocitinib

1 interaction

Avoid/Use Alternative

asciminib + abrocitinib

avoid combo if also combined w/ moderate or strong CYP2C19 inhibitor; otherwise, monitor thrombosis s/sx, especially if asciminib 200 mg bid: combo may incr. abrocitinib and active metabolite levels, risk of serious infection, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• alpelisib
Scemblix (asciminib)

+

alpelisib

1 interaction

Avoid/Use Alternative

asciminib + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• alprazolam
Scemblix (asciminib)

+

alprazolam

1 interaction

Avoid/Use Alternative

asciminib + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• apixaban
Scemblix (asciminib)

+

apixaban

1 interaction

Avoid/Use Alternative

asciminib + apixaban

ADULT PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, decr. apixaban 5mg bid or 10 mg bid dose by 50% or avoid combo if already on 2.5 mg bid; PEDS PTS: monitor bleeding s/sx; if also combined w/ strong CYP3A4 inhibitor, consider decr. apixaban dose: combo may incr. apixaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• arsenic trioxide
Scemblix (asciminib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

asciminib + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Scemblix (asciminib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

asciminib + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bosentan
Scemblix (asciminib)

+

bosentan

1 interaction

Avoid/Use Alternative

asciminib + bosentan

avoid combo if also combined w/ strong-mod CYP3A4 inhibitor; otherwise, caution advised, especially if asciminib 200 mg bid: combo may incr. bosentan levels, risk of adverse effects (hepatic metab. inhibited)

• chloramphenicol
Scemblix (asciminib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

asciminib + chloramphenicol

use alternative or monitor CBC: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• cladribine oral
Scemblix (asciminib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

asciminib + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport possibly inhibited, additive effects)

• codeine
Scemblix (asciminib)

+

codeine

1 interaction

Avoid/Use Alternative

asciminib + codeine

use alternative or monitor resp. rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite morphine)

• dabigatran
Scemblix (asciminib)

+

dabigatran

1 interaction

Avoid/Use Alternative

asciminib + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (incl. life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited)

• deferiprone
Scemblix (asciminib)

+

deferiprone

1 interaction

Avoid/Use Alternative

asciminib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• domperidone
Scemblix (asciminib)

+

domperidone

1 interaction

Avoid/Use Alternative

asciminib + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dronedarone
Scemblix (asciminib)

+

dronedarone

1 interaction

Avoid/Use Alternative

asciminib + dronedarone

use alternative or monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• ensartinib
Scemblix (asciminib)

+

ensartinib

1 interaction

Avoid/Use Alternative

asciminib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• ephedra
Scemblix (asciminib)

+

ephedra

1 interaction

Avoid/Use Alternative

asciminib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

• epinephrine inhaled
Scemblix (asciminib)

+

epinephrine inhaled

1 interaction

Avoid/Use Alternative

asciminib + epinephrine inhaled

avoid combo: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• epirubicin
Scemblix (asciminib)

+

epirubicin

1 interaction

Avoid/Use Alternative

asciminib + epirubicin

use alternative or monitor thrombosis s/sx, cardiac fxn, incl. ECG, LVEF: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, thromboembolism (additive effects)

• erdafitinib
Scemblix (asciminib)

+

erdafitinib

1 interaction

Avoid/Use Alternative

asciminib + erdafitinib

use alternative or monitor phosphate, especially if asciminib 200 mg bid: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• etrasimod
Scemblix (asciminib)

+

etrasimod

1 interaction

Avoid/Use Alternative

asciminib + etrasimod

if also combined w/ moderate or strong CYP3A4 inhibitor, avoid combo, especially if asciminib 200 mg bid; otherwise, monitor BP: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• fexinidazole
Scemblix (asciminib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

asciminib + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after asciminib D/C; use alternative or monitor CBC, ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression; may decr. fexinidazole active metabolite levels, efficacy if asciminib 200 mg bid (additive effects; hepatic metab. inhibited, decr. conversion to active metabolites)

• fosfomycin injection
Scemblix (asciminib)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

asciminib + fosfomycin injection

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• furosemide
Scemblix (asciminib)

+

furosemide

1 interaction

Avoid/Use Alternative

asciminib + furosemide

use alternative or monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ganciclovir
Scemblix (asciminib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

asciminib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydrocodone
Scemblix (asciminib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

asciminib + hydrocodone

use alternative or monitor resp. rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• hydroxychloroquine
Scemblix (asciminib)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

asciminib + hydroxychloroquine

use alternative or monitor CBC, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression (additive effects)

• idarubicin
Scemblix (asciminib)

+

idarubicin

1 interaction

Avoid/Use Alternative

asciminib + idarubicin

use alternative at least 5 half-lives after asciminib D/C; otherwise, monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• itraconazole
Scemblix (asciminib)

+

itraconazole

1 interaction

Avoid/Use Alternative

asciminib + itraconazole

avoid combo if itraconazole oral solution; otherwise, monitor cardiac fxn; if on asciminib 200 mg bid, monitor CBC: combo w/ itraconazole oral solution may decr. asciminib levels, efficacy; may incr. asciminib levels, risk of myelosuppression, cardiotoxicity, other adverse effects (absorption decr. due to hydroxypropyl-beta-cyclodextrin; hepatic metab. inhibited, additive effects)

• lefamulin
Scemblix (asciminib)

+

lefamulin

1 interaction

Avoid/Use Alternative

asciminib + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Scemblix (asciminib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

asciminib + lonafarnib

use alternative or monitor HR, ECG, electrolytes, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• macitentan
Scemblix (asciminib)

+

macitentan

1 interaction

Avoid/Use Alternative

asciminib + macitentan

if also combined w/ mod CYP3A4 inhibitor, avoid combo; otherwise, caution advised, especially if asciminib 200 mg bid: combo may incr. macitentan levels, risk of adverse effects (hepatic metab. inhibited)

• meloxicam
Scemblix (asciminib)

+

meloxicam

1 interaction

Avoid/Use Alternative

asciminib + meloxicam

avoid combo if meloxicam given as fixed-dose combo w/ rizatriptan; otherwise, monitor BP, bleeding or thrombosis s/sx, especially if asciminib 200 mg bid; use lowest effective meloxicam dose, shortest duration of concomitant tx: combo may incr. meloxicam levels, risk of GI or other bleeding (incl. life-threatening), HTN, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• meperidine
Scemblix (asciminib)

+

meperidine

1 interaction

Avoid/Use Alternative

asciminib + meperidine

use alternative or monitor resp. rate, ECG: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• methadone
Scemblix (asciminib)

+

methadone

1 interaction

Avoid/Use Alternative

asciminib + methadone

use alternative or monitor resp. rate, ECG and consider decr. methadone dose, especially if asciminib 200 mg bid: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• midodrine
Scemblix (asciminib)

+

midodrine

1 interaction

Avoid/Use Alternative

asciminib + midodrine

use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

• mobocertinib
Scemblix (asciminib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

asciminib + mobocertinib

use alternative or monitor ECG, electrolytes, cardiac fxn, incl. LVEF: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• neratinib
Scemblix (asciminib)

+

neratinib

1 interaction

Avoid/Use Alternative

asciminib + neratinib

avoid combo if also combined w/ mod-strong CYP3A4 inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• oxycodone
Scemblix (asciminib)

+

oxycodone

1 interaction

Avoid/Use Alternative

asciminib + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose;: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pacritinib
Scemblix (asciminib)

+

pacritinib

1 interaction

Avoid/Use Alternative

asciminib + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• palifermin
Scemblix (asciminib)

+

palifermin

1 interaction

Avoid/Use Alternative

asciminib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• pazopanib
Scemblix (asciminib)

+

pazopanib

1 interaction

Avoid/Use Alternative

asciminib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, HTN, thromboembolism, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

• penicillamine
Scemblix (asciminib)

+

penicillamine

1 interaction

Avoid/Use Alternative

asciminib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Scemblix (asciminib)

+

pentamidine

1 interaction

Avoid/Use Alternative

asciminib + pentamidine

use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• pirfenidone
Scemblix (asciminib)

+

pirfenidone

1 interaction

Avoid/Use Alternative

asciminib + pirfenidone

avoid combo if also combined w/ mod-strong CYP1A2 inhibitor; otherwise, caution advised, especially if asciminib 200 mg bid: combo may incr. pirfenidone levels, risk of adverse effects (hepatic metab. inhibited)

• pralsetinib
Scemblix (asciminib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

asciminib + pralsetinib

use alternative or monitor BP, consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• primaquine
Scemblix (asciminib)

+

primaquine

1 interaction

Avoid/Use Alternative

asciminib + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• propafenone
Scemblix (asciminib)

+

propafenone

1 interaction

Avoid/Use Alternative

asciminib + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor cardiac fxn, incl. ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• quizartinib
Scemblix (asciminib)

+

quizartinib

1 interaction

Avoid/Use Alternative

asciminib + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rabies vaccine
Scemblix (asciminib)

+

rabies vaccine

1 interaction

Avoid/Use Alternative

asciminib + rabies vaccine

if possible, avoid immunosuppressive tx or vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• radium Ra 223 dichloride
Scemblix (asciminib)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

asciminib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• relugolix
Scemblix (asciminib)

+

relugolix

1 interaction

Avoid/Use Alternative

asciminib + relugolix

PROSTATE CANCER: may hold relugolix if asciminib tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before asciminib; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before asciminib: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• repotrectinib
Scemblix (asciminib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

asciminib + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited)

• rivaroxaban
Scemblix (asciminib)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

asciminib + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (BCRP-mediated transport possibly inhibited, P-gp-mediated transport possibly inhibited)

• ropeginterferon alfa-2b
Scemblix (asciminib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

asciminib + ropeginterferon alfa-2b

use alternative or monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• simvastatin
Scemblix (asciminib)

+

simvastatin

1 interaction

Avoid/Use Alternative

asciminib + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, BCRP-mediated transport possibly inhibited)

• sirolimus albumin-bound
Scemblix (asciminib)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

asciminib + sirolimus albumin-bound

avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited)

• sotalol
Scemblix (asciminib)

+

sotalol

1 interaction

Avoid/Use Alternative

asciminib + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• topotecan
Scemblix (asciminib)

+

topotecan

1 interaction

Avoid/Use Alternative

asciminib + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

• toremifene
Scemblix (asciminib)

+

toremifene

1 interaction

Avoid/Use Alternative

asciminib + toremifene

use alternative or monitor ECG, thrombosis s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, thromboembolism (additive effects)

• tranexamic acid
Scemblix (asciminib)

+

tranexamic acid

1 interaction

Avoid/Use Alternative

asciminib + tranexamic acid

avoid combo: combo may incr. risk of thromboembolism (additive effects)

• vaccinia immune globulin
Scemblix (asciminib)

+

vaccinia immune globulin

1 interaction

Avoid/Use Alternative

asciminib + vaccinia immune globulin

use alternative or monitor thrombosis s/sx; use lowest vaccinia immune globulin concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• valganciclovir
Scemblix (asciminib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

asciminib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Scemblix (asciminib)

+

vandetanib

1 interaction

Avoid/Use Alternative

asciminib + vandetanib

use alternative or monitor electrolytes, BP, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, cardiotoxicity (additive effects)

• venetoclax
Scemblix (asciminib)

+

venetoclax

1 interaction

Avoid/Use Alternative

asciminib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited)

• ziprasidone
Scemblix (asciminib)

+

ziprasidone

1 interaction

Avoid/Use Alternative

asciminib + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abemaciclib
Scemblix (asciminib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

asciminib + abemaciclib

monitor CBC, thrombosis s/sx: combo may incr. abemaciclib levels, risk of myelosuppression, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• abiraterone acetate
Scemblix (asciminib)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

asciminib + abiraterone acetate

monitor BP: combo may incr. risk of HTN (additive effects)

• acalabrutinib
Scemblix (asciminib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

asciminib + acalabrutinib

monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• acebutolol
Scemblix (asciminib)

+

acebutolol

1 interaction

Monitor/Modify Tx

asciminib + acebutolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• adagrasib
Scemblix (asciminib)

+

adagrasib

1 interaction

Monitor/Modify Tx

asciminib + adagrasib

if asciminib 200 mg bid, monitor CBC, ECG, electrolytes; otherwise, monitor ECG, electrolytes: combo may incr. asciminib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• adalimumab
Scemblix (asciminib)

+

adalimumab

1 interaction

Monitor/Modify Tx

asciminib + adalimumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• ado-trastuzumab emtansine
Scemblix (asciminib)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

asciminib + ado-trastuzumab emtansine

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• afatinib
Scemblix (asciminib)

+

afatinib

1 interaction

Monitor/Modify Tx

asciminib + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• aflibercept
Scemblix (asciminib)

+

aflibercept

1 interaction

Monitor/Modify Tx

asciminib + aflibercept

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• albendazole
Scemblix (asciminib)

+

albendazole

1 interaction

Monitor/Modify Tx

asciminib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• albuterol
Scemblix (asciminib)

+

albuterol

1 interaction

Monitor/Modify Tx

asciminib + albuterol

monitor BP: combo may incr. risk of HTN (additive effects)

• albuterol inhaled
Scemblix (asciminib)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + albuterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• aldesleukin
Scemblix (asciminib)

+

aldesleukin

1 interaction

Monitor/Modify Tx

asciminib + aldesleukin

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• alemtuzumab
Scemblix (asciminib)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

asciminib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• alfentanil
Scemblix (asciminib)

+

alfentanil

1 interaction

Monitor/Modify Tx

asciminib + alfentanil

monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• aliskiren
Scemblix (asciminib)

+

aliskiren

1 interaction

Monitor/Modify Tx

asciminib + aliskiren

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• allopurinol
Scemblix (asciminib)

+

allopurinol

1 interaction

Monitor/Modify Tx

asciminib + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• almotriptan
Scemblix (asciminib)

+

almotriptan

1 interaction

Monitor/Modify Tx

asciminib + almotriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• alogliptin
Scemblix (asciminib)

+

alogliptin

1 interaction

Monitor/Modify Tx

asciminib + alogliptin

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• amiloride
Scemblix (asciminib)

+

amiloride

1 interaction

Monitor/Modify Tx

asciminib + amiloride

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• aminocaproic acid
Scemblix (asciminib)

+

aminocaproic acid

1 interaction

Monitor/Modify Tx

asciminib + aminocaproic acid

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• amiodarone
Scemblix (asciminib)

+

amiodarone

1 interaction

Monitor/Modify Tx

asciminib + amiodarone

monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• amlodipine
Scemblix (asciminib)

+

amlodipine

1 interaction

Monitor/Modify Tx

asciminib + amlodipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• amphetamine
Scemblix (asciminib)

+

amphetamine

1 interaction

Monitor/Modify Tx

asciminib + amphetamine

monitor BP: combo may incr. risk of HTN (additive effects)

• anagrelide
Scemblix (asciminib)

+

anagrelide

1 interaction

Monitor/Modify Tx

asciminib + anagrelide

monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• angiotensin II
Scemblix (asciminib)

+

angiotensin II

1 interaction

Monitor/Modify Tx

asciminib + angiotensin II

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• anthrax immune globulin
Scemblix (asciminib)

+

anthrax immune globulin

1 interaction

Monitor/Modify Tx

asciminib + anthrax immune globulin

monitor thrombosis s/sx; use lowest anthrax immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• anthrax vaccine
Scemblix (asciminib)

+

anthrax vaccine

1 interaction

Monitor/Modify Tx

asciminib + anthrax vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-inhibitor coagulant complex
Scemblix (asciminib)

+

anti-inhibitor coagulant complex

1 interaction

Monitor/Modify Tx

asciminib + anti-inhibitor coagulant complex

monitor thrombosis s/sx, especially w/ anti-inhibitor coagulant complex dose >100 units/kg: combo may incr. risk of thromboembolism (additive effects)

• anti-thymocyte globulin
Scemblix (asciminib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

asciminib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• antihemophilic factor (factor VIII)/von Willebrand factor complex
Scemblix (asciminib)

+

antihemophilic factor (factor VIII)/ von Willebrand factor complex

1 interaction

Monitor/Modify Tx

asciminib + antihemophilic factor (factor VIII)/ von Willebrand factor complex

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• apalutamide
Scemblix (asciminib)

+

apalutamide

1 interaction

Monitor/Modify Tx

asciminib + apalutamide

monitor ECG: combo may decr. asciminib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apomorphine
Scemblix (asciminib)

+

apomorphine

1 interaction

Monitor/Modify Tx

asciminib + apomorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprocitentan
Scemblix (asciminib)

+

aprocitentan

1 interaction

Monitor/Modify Tx

asciminib + aprocitentan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• arformoterol inhaled
Scemblix (asciminib)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + arformoterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• armodafinil
Scemblix (asciminib)

+

armodafinil

1 interaction

Monitor/Modify Tx

asciminib + armodafinil

monitor BP: combo may incr. risk of HTN (additive effects)

• artemether/lumefantrine
Scemblix (asciminib)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

asciminib + artemether/ lumefantrine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Scemblix (asciminib)

+

asenapine

1 interaction

Monitor/Modify Tx

asciminib + asenapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asparaginase
Scemblix (asciminib)

+

asparaginase

1 interaction

Monitor/Modify Tx

asciminib + asparaginase

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• atazanavir
Scemblix (asciminib)

+

atazanavir

1 interaction

Monitor/Modify Tx

asciminib + atazanavir

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• atenolol
Scemblix (asciminib)

+

atenolol

1 interaction

Monitor/Modify Tx

asciminib + atenolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• atidarsagene autotemcel
Scemblix (asciminib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

asciminib + atidarsagene autotemcel

monitor CBC, bleeding or thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• atogepant
Scemblix (asciminib)

+

atogepant

1 interaction

Monitor/Modify Tx

asciminib + atogepant

monitor BP: combo may incr. risk of HTN (additive effects)

• atomoxetine
Scemblix (asciminib)

+

atomoxetine

1 interaction

Monitor/Modify Tx

asciminib + atomoxetine

monitor BP: combo may incr. risk of HTN (additive effects)

• atorvastatin
Scemblix (asciminib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

asciminib + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

• atropine ophthalmic
Scemblix (asciminib)

+

atropine ophthalmic

1 interaction

Monitor/Modify Tx

asciminib + atropine ophthalmic

monitor BP: combo may incr. risk of HTN (additive effects)

• auranofin
Scemblix (asciminib)

+

auranofin

1 interaction

Monitor/Modify Tx

asciminib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avanafil
Scemblix (asciminib)

+

avanafil

1 interaction

Monitor/Modify Tx

asciminib + avanafil

monitor BP; consider decr. avanafil dose: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avapritinib
Scemblix (asciminib)

+

avapritinib

1 interaction

Monitor/Modify Tx

asciminib + avapritinib

monitor bleeding s/sx: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• avatrombopag
Scemblix (asciminib)

+

avatrombopag

1 interaction

Monitor/Modify Tx

asciminib + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP3A4 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP3A4 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• avelumab
Scemblix (asciminib)

+

avelumab

1 interaction

Monitor/Modify Tx

asciminib + avelumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• axitinib
Scemblix (asciminib)

+

axitinib

1 interaction

Monitor/Modify Tx

asciminib + axitinib

monitor BP, cardiac fxn, thrombosis s/sx: combo may incr. risk of HTN, cardiotoxicity, thromboembolism (additive effects)

• azathioprine
Scemblix (asciminib)

+

azathioprine

1 interaction

Monitor/Modify Tx

asciminib + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azilsartan medoxomil
Scemblix (asciminib)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

asciminib + azilsartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• azithromycin
Scemblix (asciminib)

+

azithromycin

1 interaction

Monitor/Modify Tx

asciminib + azithromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• balsalazide
Scemblix (asciminib)

+

balsalazide

1 interaction

Monitor/Modify Tx

asciminib + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Scemblix (asciminib)

+

baricitinib

1 interaction

Monitor/Modify Tx

asciminib + baricitinib

monitor CBC, thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• bazedoxifene
Scemblix (asciminib)

+

bazedoxifene

1 interaction

Monitor/Modify Tx

asciminib + bazedoxifene

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• benazepril
Scemblix (asciminib)

+

benazepril

1 interaction

Monitor/Modify Tx

asciminib + benazepril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• benznidazole
Scemblix (asciminib)

+

benznidazole

1 interaction

Monitor/Modify Tx

asciminib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benzphetamine
Scemblix (asciminib)

+

benzphetamine

1 interaction

Monitor/Modify Tx

asciminib + benzphetamine

monitor BP: combo may incr. risk of HTN (additive effects)

• betamethasone
Scemblix (asciminib)

+

betamethasone

1 interaction

Monitor/Modify Tx

asciminib + betamethasone

monitor BP: combo may incr. risk of HTN (additive effects)

• betaxolol
Scemblix (asciminib)

+

betaxolol

1 interaction

Monitor/Modify Tx

asciminib + betaxolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• betibeglogene autotemcel
Scemblix (asciminib)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

asciminib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Scemblix (asciminib)

+

bevacizumab

1 interaction

Monitor/Modify Tx

asciminib + bevacizumab

monitor BP, cardiac fxn, thrombosis s/sx: combo may incr. risk of HTN, cardiotoxicity, thromboembolism (additive effects)

• bezlotoxumab
Scemblix (asciminib)

+

bezlotoxumab

1 interaction

Monitor/Modify Tx

asciminib + bezlotoxumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• binimetinib
Scemblix (asciminib)

+

binimetinib

1 interaction

Monitor/Modify Tx

asciminib + binimetinib

monitor thrombosis s/sx, cardiac fxn, incl. LVEF: combo may incr. risk of thromboembolism, cardiotoxicity (additive effects)

• bismuth subsalicylate
Scemblix (asciminib)

+

bismuth subsalicylate

1 interaction

Monitor/Modify Tx

asciminib + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

• bisoprolol
Scemblix (asciminib)

+

bisoprolol

1 interaction

Monitor/Modify Tx

asciminib + bisoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• bortezomib
Scemblix (asciminib)

+

bortezomib

1 interaction

Monitor/Modify Tx

asciminib + bortezomib

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• bosutinib
Scemblix (asciminib)

+

bosutinib

1 interaction

Monitor/Modify Tx

asciminib + bosutinib

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• botulism immune globulin
Scemblix (asciminib)

+

botulism immune globulin

1 interaction

Monitor/Modify Tx

asciminib + botulism immune globulin

monitor thrombosis s/sx; use lowest botulism immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• brigatinib
Scemblix (asciminib)

+

brigatinib

1 interaction

Monitor/Modify Tx

asciminib + brigatinib

monitor BP, HR: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• brolucizumab
Scemblix (asciminib)

+

brolucizumab

1 interaction

Monitor/Modify Tx

asciminib + brolucizumab

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• budesonide
Scemblix (asciminib)

+

budesonide

1 interaction

Monitor/Modify Tx

asciminib + budesonide

monitor BP: combo may incr. risk of HTN (additive effects)

• bumetanide
Scemblix (asciminib)

+

bumetanide

1 interaction

Monitor/Modify Tx

asciminib + bumetanide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• bupropion
Scemblix (asciminib)

+

bupropion

1 interaction

Monitor/Modify Tx

asciminib + bupropion

monitor BP: combo may incr. risk of HTN (additive effects)

• C1 esterase inhibitor
Scemblix (asciminib)

+

C1 esterase inhibitor

1 interaction

Monitor/Modify Tx

asciminib + C1 esterase inhibitor

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• cabozantinib
Scemblix (asciminib)

+

cabozantinib

1 interaction

Monitor/Modify Tx

asciminib + cabozantinib

monitor ECG, BP, thrombosis s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, thromboembolism (additive effects)

• caffeine
Scemblix (asciminib)

+

caffeine

1 interaction

Monitor/Modify Tx

asciminib + caffeine

monitor BP; avoid excessive caffeine intake: combo may incr. risk of HTN (additive effects)

• caffeine citrate
Scemblix (asciminib)

+

caffeine citrate

1 interaction

Monitor/Modify Tx

asciminib + caffeine citrate

monitor BP: combo may incr. risk of HTN (additive effects)

• calaspargase
Scemblix (asciminib)

+

calaspargase

1 interaction

Monitor/Modify Tx

asciminib + calaspargase

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• candesartan cilexetil
Scemblix (asciminib)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

asciminib + candesartan cilexetil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• cannabis
Scemblix (asciminib)

+

cannabis

1 interaction

Monitor/Modify Tx

asciminib + cannabis

monitor BP: combo may incr. risk of HTN (additive effects)

• capecitabine
Scemblix (asciminib)

+

capecitabine

1 interaction

Monitor/Modify Tx

asciminib + capecitabine

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• capivasertib
Scemblix (asciminib)

+

capivasertib

1 interaction

Monitor/Modify Tx

asciminib + capivasertib

monitor glucose: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• captopril
Scemblix (asciminib)

+

captopril

1 interaction

Monitor/Modify Tx

asciminib + captopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• carbamazepine
Scemblix (asciminib)

+

carbamazepine

1 interaction

Monitor/Modify Tx

asciminib + carbamazepine

monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects; may decr. asciminib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• carfilzomib
Scemblix (asciminib)

+

carfilzomib

1 interaction

Monitor/Modify Tx

asciminib + carfilzomib

monitor cardiac fxn, BP, thrombosis s/sx: combo may incr. risk of cardiotoxicity, HTN, thromboembolism (additive effects)

• carvedilol
Scemblix (asciminib)

+

carvedilol

1 interaction

Monitor/Modify Tx

asciminib + carvedilol

monitor BP, HR, especially if asciminib 200 mg bid: combo may incr. carvedilol levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• celecoxib
Scemblix (asciminib)

+

celecoxib

1 interaction

Monitor/Modify Tx

asciminib + celecoxib

monitor BP, bleeding or thrombosis s/sx; consider decr. celecoxib dose, especially if asciminib 200 mg bid; use lowest effective celecoxib dose, shortest effective tx duration: combo may incr. celecoxib levels, risk of GI or other bleeding (incl. life-threatening), thromboembolism, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• ceritinib
Scemblix (asciminib)

+

ceritinib

1 interaction

Monitor/Modify Tx

asciminib + ceritinib

if asciminib 200 mg bid, monitor ECG, electrolytes, CBC; otherwise, monitor ECG, electrolytes: combo may incr. asciminib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• certolizumab pegol
Scemblix (asciminib)

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

asciminib + certolizumab pegol

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• chikungunya vaccine
Scemblix (asciminib)

+

chikungunya vaccine

1 interaction

Monitor/Modify Tx

asciminib + chikungunya vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chloroquine
Scemblix (asciminib)

+

chloroquine

1 interaction

Monitor/Modify Tx

asciminib + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorothiazide
Scemblix (asciminib)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

asciminib + chlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• chlorthalidone
Scemblix (asciminib)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

asciminib + chlorthalidone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• chorionic gonadotropin
Scemblix (asciminib)

+

chorionic gonadotropin

1 interaction

Monitor/Modify Tx

asciminib + chorionic gonadotropin

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• cidofovir
Scemblix (asciminib)

+

cidofovir

1 interaction

Monitor/Modify Tx

asciminib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Scemblix (asciminib)

+

cilostazol

1 interaction

Monitor/Modify Tx

asciminib + cilostazol

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• citalopram
Scemblix (asciminib)

+

citalopram

1 interaction

Monitor/Modify Tx

asciminib + citalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clarithromycin
Scemblix (asciminib)

+

clarithromycin

1 interaction

Monitor/Modify Tx

asciminib + clarithromycin

if asciminib 200 mg bid, monitor ECG, CBC; otherwise, monitor ECG: combo may incr. asciminib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• clevidipine
Scemblix (asciminib)

+

clevidipine

1 interaction

Monitor/Modify Tx

asciminib + clevidipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clofazimine
Scemblix (asciminib)

+

clofazimine

1 interaction

Monitor/Modify Tx

asciminib + clofazimine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonidine
Scemblix (asciminib)

+

clonidine

1 interaction

Monitor/Modify Tx

asciminib + clonidine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• clozapine
Scemblix (asciminib)

+

clozapine

1 interaction

Monitor/Modify Tx

asciminib + clozapine

monitor CBC, thrombosis s/sx, cardiac fxn, incl. ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, cardiotoxicity, thromboembolism, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• coagulation factor IX
Scemblix (asciminib)

+

coagulation factor IX

1 interaction

Monitor/Modify Tx

asciminib + coagulation factor IX

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor VIIa
Scemblix (asciminib)

+

coagulation factor VIIa

1 interaction

Monitor/Modify Tx

asciminib + coagulation factor VIIa

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• coagulation factor XIII A-subunit
Scemblix (asciminib)

+

coagulation factor XIII A-subunit

1 interaction

Monitor/Modify Tx

asciminib + coagulation factor XIII A-subunit

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• cobicistat
Scemblix (asciminib)

+

cobicistat

1 interaction

Monitor/Modify Tx

asciminib + cobicistat

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• cobimetinib
Scemblix (asciminib)

+

cobimetinib

1 interaction

Monitor/Modify Tx

asciminib + cobimetinib

monitor cardiac fxn, incl. LVEF: combo may incr. cobimetinib levels, risk of cardiotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• cocaine
Scemblix (asciminib)

+

cocaine

1 interaction

Monitor/Modify Tx

asciminib + cocaine

monitor BP: combo may incr. risk of HTN (additive effects)

• concizumab
Scemblix (asciminib)

+

concizumab

1 interaction

Monitor/Modify Tx

asciminib + concizumab

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• copanlisib
Scemblix (asciminib)

+

copanlisib

1 interaction

Monitor/Modify Tx

asciminib + copanlisib

monitor BP: combo may incr. risk of HTN (additive effects; copanlisib may cause infusion-related HTN)

• corticotropin
Scemblix (asciminib)

+

corticotropin

1 interaction

Monitor/Modify Tx

asciminib + corticotropin

monitor BP: combo may incr. risk of HTN (additive effects)

• cortisone
Scemblix (asciminib)

+

cortisone

1 interaction

Monitor/Modify Tx

asciminib + cortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• COVID-19 vaccine
Scemblix (asciminib)

+

COVID-19 vaccine

1 interaction

Monitor/Modify Tx

asciminib + COVID-19 vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• crizotinib
Scemblix (asciminib)

+

crizotinib

1 interaction

Monitor/Modify Tx

asciminib + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cyclophosphamide
Scemblix (asciminib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

asciminib + cyclophosphamide

monitor cardiac fxn, CBC: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of cardiotoxicity, myelosuppression (hepatic metab. possibly inhibited, decr. conversion to active metabolite; additive effects)

• cyclosporine
Scemblix (asciminib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

asciminib + cyclosporine

monitor cyclosporine levels, renal fxn, BP: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, HTN, other adverse effects (P-gp-mediated transport possibly inhibited, additive effects)

• cytomegalovirus immune globulin
Scemblix (asciminib)

+

cytomegalovirus immune globulin

1 interaction

Monitor/Modify Tx

asciminib + cytomegalovirus immune globulin

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• dabrafenib
Scemblix (asciminib)

+

dabrafenib

1 interaction

Monitor/Modify Tx

asciminib + dabrafenib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• danazol
Scemblix (asciminib)

+

danazol

1 interaction

Monitor/Modify Tx

asciminib + danazol

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• dapsone
Scemblix (asciminib)

+

dapsone

1 interaction

Monitor/Modify Tx

asciminib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• darbepoetin alfa
Scemblix (asciminib)

+

darbepoetin alfa

1 interaction

Monitor/Modify Tx

asciminib + darbepoetin alfa

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• daunorubicin
Scemblix (asciminib)

+

daunorubicin

1 interaction

Monitor/Modify Tx

asciminib + daunorubicin

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• deferasirox
Scemblix (asciminib)

+

deferasirox

1 interaction

Monitor/Modify Tx

asciminib + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deflazacort
Scemblix (asciminib)

+

deflazacort

1 interaction

Monitor/Modify Tx

asciminib + deflazacort

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• degarelix
Scemblix (asciminib)

+

degarelix

1 interaction

Monitor/Modify Tx

asciminib + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Scemblix (asciminib)

+

desflurane

1 interaction

Monitor/Modify Tx

asciminib + desflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Scemblix (asciminib)

+

desipramine

1 interaction

Monitor/Modify Tx

asciminib + desipramine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desmopressin
Scemblix (asciminib)

+

desmopressin

1 interaction

Monitor/Modify Tx

asciminib + desmopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• desogestrel (contraceptive)
Scemblix (asciminib)

+

desogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + desogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• desvenlafaxine
Scemblix (asciminib)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

asciminib + desvenlafaxine

monitor BP: combo may incr. risk of HTN (additive effects)

• dexamethasone
Scemblix (asciminib)

+

dexamethasone

1 interaction

Monitor/Modify Tx

asciminib + dexamethasone

monitor BP, thrombosis s/sx, especially if multiple myeloma use: combo may incr. risk of HTN, thromboembolism (additive effects)

• dexmedetomidine
Scemblix (asciminib)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

asciminib + dexmedetomidine

monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Scemblix (asciminib)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

asciminib + dexmedetomidine injection

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmethylphenidate
Scemblix (asciminib)

+

dexmethylphenidate

1 interaction

Monitor/Modify Tx

asciminib + dexmethylphenidate

monitor BP: combo may incr. risk of HTN (additive effects)

• dexrazoxane
Scemblix (asciminib)

+

dexrazoxane

1 interaction

Monitor/Modify Tx

asciminib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• dextroamphetamine
Scemblix (asciminib)

+

dextroamphetamine

1 interaction

Monitor/Modify Tx

asciminib + dextroamphetamine

monitor BP: combo may incr. risk of HTN (additive effects)

• diclofenac
Scemblix (asciminib)

+

diclofenac

1 interaction

Monitor/Modify Tx

asciminib + diclofenac

monitor bleeding or thrombosis s/sx, BP, especially if asciminib 200 mg bid; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. diclofenac levels, risk of GI or other bleeding (incl. life-threatening), HTN, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• diclofenac topical
Scemblix (asciminib)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

asciminib + diclofenac topical

monitor BP, thrombosis s/sx; use lowest effective diclofenac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• dienogest (contraceptive)
Scemblix (asciminib)

+

dienogest (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + dienogest (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• diethylpropion
Scemblix (asciminib)

+

diethylpropion

1 interaction

Monitor/Modify Tx

asciminib + diethylpropion

monitor BP: combo may incr. risk of HTN (additive effects)

• diflunisal
Scemblix (asciminib)

+

diflunisal

1 interaction

Monitor/Modify Tx

asciminib + diflunisal

monitor BP, thrombosis s/sx; use lowest effective diflunisal dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• digoxin
Scemblix (asciminib)

+

digoxin

1 interaction

Monitor/Modify Tx

asciminib + digoxin

monitor digoxin levels, HR; consider decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport possibly inhibited)

• dihydroergotamine
Scemblix (asciminib)

+

dihydroergotamine

1 interaction

Monitor/Modify Tx

asciminib + dihydroergotamine

monitor BP: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• diltiazem
Scemblix (asciminib)

+

diltiazem

1 interaction

Monitor/Modify Tx

asciminib + diltiazem

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• diphtheria/tetanus vaccine
Scemblix (asciminib)

+

diphtheria/ tetanus vaccine

1 interaction

Monitor/Modify Tx

asciminib + diphtheria/ tetanus vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diphtheria/tetanus/pertussis vaccine
Scemblix (asciminib)

+

diphtheria/ tetanus/ pertussis vaccine

1 interaction

Monitor/Modify Tx

asciminib + diphtheria/ tetanus/ pertussis vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• disopyramide
Scemblix (asciminib)

+

disopyramide

1 interaction

Monitor/Modify Tx

asciminib + disopyramide

monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dobutamine
Scemblix (asciminib)

+

dobutamine

1 interaction

Monitor/Modify Tx

asciminib + dobutamine

monitor BP: combo may incr. risk of HTN (additive effects)

• docetaxel
Scemblix (asciminib)

+

docetaxel

1 interaction

Monitor/Modify Tx

asciminib + docetaxel

monitor CBC: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dofetilide
Scemblix (asciminib)

+

dofetilide

1 interaction

Monitor/Modify Tx

asciminib + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• donepezil
Scemblix (asciminib)

+

donepezil

1 interaction

Monitor/Modify Tx

asciminib + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dopamine
Scemblix (asciminib)

+

dopamine

1 interaction

Monitor/Modify Tx

asciminib + dopamine

monitor BP: combo may incr. risk of HTN (additive effects)

• dordaviprone
Scemblix (asciminib)

+

dordaviprone

1 interaction

Monitor/Modify Tx

asciminib + dordaviprone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxapram
Scemblix (asciminib)

+

doxapram

1 interaction

Monitor/Modify Tx

asciminib + doxapram

monitor BP: combo may incr. risk of HTN (additive effects)

• doxazosin
Scemblix (asciminib)

+

doxazosin

1 interaction

Monitor/Modify Tx

asciminib + doxazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• doxorubicin
Scemblix (asciminib)

+

doxorubicin

1 interaction

Monitor/Modify Tx

asciminib + doxorubicin

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• dronabinol
Scemblix (asciminib)

+

dronabinol

1 interaction

Monitor/Modify Tx

asciminib + dronabinol

monitor BP: combo may incr. dronabinol levels, risk of HTN, other adverse effects; may decr. dronabinol active metabolite levels, efficacy (hepatic metab. inhibited, decr. metabolite formation, additive effects)

• droperidol
Scemblix (asciminib)

+

droperidol

1 interaction

Monitor/Modify Tx

asciminib + droperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• drospirenone (contraceptive)
Scemblix (asciminib)

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + drospirenone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• drospirenone (hormone replacement)
Scemblix (asciminib)

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + drospirenone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• droxidopa
Scemblix (asciminib)

+

droxidopa

1 interaction

Monitor/Modify Tx

asciminib + droxidopa

monitor BP: combo may incr. risk of supine HTN (additive effects)

• ebola vaccine, live
Scemblix (asciminib)

+

ebola vaccine, live

1 interaction

Monitor/Modify Tx

asciminib + ebola vaccine, live

consider vaccinating at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine w/ vesicular stomatitis virus vector)

• edoxaban
Scemblix (asciminib)

+

edoxaban

1 interaction

Monitor/Modify Tx

asciminib + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• efbemalenograstim alfa
Scemblix (asciminib)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

asciminib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Scemblix (asciminib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

asciminib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• eletriptan
Scemblix (asciminib)

+

eletriptan

1 interaction

Monitor/Modify Tx

asciminib + eletriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• elivaldogene autotemcel
Scemblix (asciminib)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

asciminib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• eltrombopag
Scemblix (asciminib)

+

eltrombopag

1 interaction

Monitor/Modify Tx

asciminib + eltrombopag

monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• enalapril
Scemblix (asciminib)

+

enalapril

1 interaction

Monitor/Modify Tx

asciminib + enalapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• enalaprilat
Scemblix (asciminib)

+

enalaprilat

1 interaction

Monitor/Modify Tx

asciminib + enalaprilat

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• encorafenib
Scemblix (asciminib)

+

encorafenib

1 interaction

Monitor/Modify Tx

asciminib + encorafenib

monitor ECG, electrolytes, cardiac fxn (incl. LVEF) if encorafenib used in combo w/ binimetinib: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects; may decr. asciminib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• enfortumab vedotin
Scemblix (asciminib)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

asciminib + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport possibly inhibited)

• entrectinib
Scemblix (asciminib)

+

entrectinib

1 interaction

Monitor/Modify Tx

asciminib + entrectinib

monitor ECG, CBC, cardiac fxn, incl. LVEF: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• enzalutamide
Scemblix (asciminib)

+

enzalutamide

1 interaction

Monitor/Modify Tx

asciminib + enzalutamide

monitor BP: combo may decr. asciminib levels, efficacy; may incr. risk of HTN (hepatic metab. induced; additive effects)

• ephedrine injection
Scemblix (asciminib)

+

ephedrine injection

1 interaction

Monitor/Modify Tx

asciminib + ephedrine injection

monitor BP: combo may incr. risk of HTN (additive effects)

• ephedrine oral
Scemblix (asciminib)

+

ephedrine oral

1 interaction

Monitor/Modify Tx

asciminib + ephedrine oral

monitor BP: combo may incr. risk of HTN (additive effects)

• epinephrine
Scemblix (asciminib)

+

epinephrine

1 interaction

Monitor/Modify Tx

asciminib + epinephrine

monitor BP: combo may incr. risk of HTN (additive effects)

• eplerenone
Scemblix (asciminib)

+

eplerenone

1 interaction

Monitor/Modify Tx

asciminib + eplerenone

monitor potassium, BP: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• epoetin alfa
Scemblix (asciminib)

+

epoetin alfa

1 interaction

Monitor/Modify Tx

asciminib + epoetin alfa

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• eptinezumab
Scemblix (asciminib)

+

eptinezumab

1 interaction

Monitor/Modify Tx

asciminib + eptinezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• erenumab
Scemblix (asciminib)

+

erenumab

1 interaction

Monitor/Modify Tx

asciminib + erenumab

monitor BP: combo may incr. risk of HTN (additive effects)

• ergotamine
Scemblix (asciminib)

+

ergotamine

1 interaction

Monitor/Modify Tx

asciminib + ergotamine

monitor BP: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• eribulin
Scemblix (asciminib)

+

eribulin

1 interaction

Monitor/Modify Tx

asciminib + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Scemblix (asciminib)

+

erythromycin

1 interaction

Monitor/Modify Tx

asciminib + erythromycin

monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• esketamine
Scemblix (asciminib)

+

esketamine

1 interaction

Monitor/Modify Tx

asciminib + esketamine

monitor BP: combo may incr. risk of HTN (additive effects)

• esmolol
Scemblix (asciminib)

+

esmolol

1 interaction

Monitor/Modify Tx

asciminib + esmolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• estetrol (contraceptive)
Scemblix (asciminib)

+

estetrol (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + estetrol (contraceptive)

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• estradiol (contraceptive)
Scemblix (asciminib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + estradiol (contraceptive)

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• estradiol (hormone replacement)
Scemblix (asciminib)

+

estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + estradiol (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• estrogens, conjugated (hormone replacement)
Scemblix (asciminib)

+

estrogens, conjugated (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + estrogens, conjugated (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• estrogens, esterified (hormone replacement)
Scemblix (asciminib)

+

estrogens, esterified (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + estrogens, esterified (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• etanercept
Scemblix (asciminib)

+

etanercept

1 interaction

Monitor/Modify Tx

asciminib + etanercept

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• ethacrynic acid
Scemblix (asciminib)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

asciminib + ethacrynic acid

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ethinyl estradiol (contraceptive)
Scemblix (asciminib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + ethinyl estradiol (contraceptive)

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• ethinyl estradiol (hormone replacement)
Scemblix (asciminib)

+

ethinyl estradiol (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + ethinyl estradiol (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• ethynodiol (contraceptive)
Scemblix (asciminib)

+

ethynodiol (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + ethynodiol (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• etodolac
Scemblix (asciminib)

+

etodolac

1 interaction

Monitor/Modify Tx

asciminib + etodolac

monitor BP, thrombosis s/sx; use lowest effective etodolac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• etonogestrel (contraceptive)
Scemblix (asciminib)

+

etonogestrel (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + etonogestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• everolimus
Scemblix (asciminib)

+

everolimus

1 interaction

Monitor/Modify Tx

asciminib + everolimus

monitor thrombosis s/sx, especially if immunosuppressant use; TSC-ASSOC. SEGA, TSC-ASSOC. PARTIAL ONSET SEIZURES, TRANSPLANT: monitor everolimus levels, CBC; OTHER INDICATIONS: monitor CBC: combo may incr. everolimus levels, risk of myelosuppression, thromboembolism, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• exagamglogene autotemcel
Scemblix (asciminib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

asciminib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• factor XIII concentrate
Scemblix (asciminib)

+

factor XIII concentrate

1 interaction

Monitor/Modify Tx

asciminib + factor XIII concentrate

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• fam-trastuzumab deruxtecan
Scemblix (asciminib)

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

asciminib + fam-trastuzumab deruxtecan

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• faricimab
Scemblix (asciminib)

+

faricimab

1 interaction

Monitor/Modify Tx

asciminib + faricimab

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• fedratinib
Scemblix (asciminib)

+

fedratinib

1 interaction

Monitor/Modify Tx

asciminib + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs, thrombosis s/sx; otherwise, monitor thrombosis s/sx: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• felodipine
Scemblix (asciminib)

+

felodipine

1 interaction

Monitor/Modify Tx

asciminib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• fenfluramine
Scemblix (asciminib)

+

fenfluramine

1 interaction

Monitor/Modify Tx

asciminib + fenfluramine

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• fenofibrate
Scemblix (asciminib)

+

fenofibrate

1 interaction

Monitor/Modify Tx

asciminib + fenofibrate

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• fenofibric acid
Scemblix (asciminib)

+

fenofibric acid

1 interaction

Monitor/Modify Tx

asciminib + fenofibric acid

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• fenoldopam
Scemblix (asciminib)

+

fenoldopam

1 interaction

Monitor/Modify Tx

asciminib + fenoldopam

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fenoprofen
Scemblix (asciminib)

+

fenoprofen

1 interaction

Monitor/Modify Tx

asciminib + fenoprofen

monitor BP, thrombosis s/sx; use lowest effective fenoprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• fentanyl
Scemblix (asciminib)

+

fentanyl

1 interaction

Monitor/Modify Tx

asciminib + fentanyl

monitor resp. rate; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• filgrastim (G-CSF)
Scemblix (asciminib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

asciminib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• finerenone
Scemblix (asciminib)

+

finerenone

1 interaction

Monitor/Modify Tx

asciminib + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• fingolimod
Scemblix (asciminib)

+

fingolimod

1 interaction

Monitor/Modify Tx

asciminib + fingolimod

monitor BP: combo may incr. risk of HTN (additive effects)

• fitusiran
Scemblix (asciminib)

+

fitusiran

1 interaction

Monitor/Modify Tx

asciminib + fitusiran

monitor antithrombin activity level, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• flecainide
Scemblix (asciminib)

+

flecainide

1 interaction

Monitor/Modify Tx

asciminib + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flibanserin
Scemblix (asciminib)

+

flibanserin

1 interaction

Monitor/Modify Tx

asciminib + flibanserin

monitor BP, especially if flibanserin also combined w/ other weak CYP3A4 inhibitors: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited)

• flucytosine
Scemblix (asciminib)

+

flucytosine

1 interaction

Monitor/Modify Tx

asciminib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludrocortisone
Scemblix (asciminib)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

asciminib + fludrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• fluorouracil
Scemblix (asciminib)

+

fluorouracil

1 interaction

Monitor/Modify Tx

asciminib + fluorouracil

monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• fluphenazine
Scemblix (asciminib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

asciminib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flurbiprofen
Scemblix (asciminib)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

asciminib + flurbiprofen

monitor BP, thrombosis s/sx; use lowest effective flurbiprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• fluvastatin
Scemblix (asciminib)

+

fluvastatin

1 interaction

Monitor/Modify Tx

asciminib + fluvastatin

monitor CK, myopathy sx, especially if asciminib 200 mg bid: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, BCRP-mediated transport possibly inhibited)

• follitropin
Scemblix (asciminib)

+

follitropin

1 interaction

Monitor/Modify Tx

asciminib + follitropin

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• formoterol inhaled
Scemblix (asciminib)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + formoterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• foscarnet
Scemblix (asciminib)

+

foscarnet

1 interaction

Monitor/Modify Tx

asciminib + foscarnet

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fosinopril
Scemblix (asciminib)

+

fosinopril

1 interaction

Monitor/Modify Tx

asciminib + fosinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• fosphenytoin
Scemblix (asciminib)

+

fosphenytoin

1 interaction

Monitor/Modify Tx

asciminib + fosphenytoin

monitor phenytoin levels, especially if asciminib 200 mg bid: combo may incr. phenytoin levels, risk of toxicity; may decr. asciminib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• fostamatinib
Scemblix (asciminib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

asciminib + fostamatinib

monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

• fremanezumab
Scemblix (asciminib)

+

fremanezumab

1 interaction

Monitor/Modify Tx

asciminib + fremanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• frovatriptan
Scemblix (asciminib)

+

frovatriptan

1 interaction

Monitor/Modify Tx

asciminib + frovatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• fruquintinib
Scemblix (asciminib)

+

fruquintinib

1 interaction

Monitor/Modify Tx

asciminib + fruquintinib

monitor BP, thrombosis s/sx: combo may incr. risk of thromboembolism, HTN, incl. hypertensive crisis (additive effects)

• galcanezumab
Scemblix (asciminib)

+

galcanezumab

1 interaction

Monitor/Modify Tx

asciminib + galcanezumab

monitor BP: combo may incr. risk of HTN (additive effects)

• gepirone
Scemblix (asciminib)

+

gepirone

1 interaction

Monitor/Modify Tx

asciminib + gepirone

monitor ECG, electrolytes: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• gilteritinib
Scemblix (asciminib)

+

gilteritinib

1 interaction

Monitor/Modify Tx

asciminib + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• givinostat
Scemblix (asciminib)

+

givinostat

1 interaction

Monitor/Modify Tx

asciminib + givinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glasdegib
Scemblix (asciminib)

+

glasdegib

1 interaction

Monitor/Modify Tx

asciminib + glasdegib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glimepiride
Scemblix (asciminib)

+

glimepiride

1 interaction

Monitor/Modify Tx

asciminib + glimepiride

monitor glucose, especially if asciminib 200 mg bid: combo may incr. glimepiride levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• glipizide
Scemblix (asciminib)

+

glipizide

1 interaction

Monitor/Modify Tx

asciminib + glipizide

monitor glucose, especially if asciminib 200 mg bid: combo may incr. glipizide levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• glyburide
Scemblix (asciminib)

+

glyburide

1 interaction

Monitor/Modify Tx

asciminib + glyburide

monitor glucose, especially if asciminib 200 mg bid: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• golimumab
Scemblix (asciminib)

+

golimumab

1 interaction

Monitor/Modify Tx

asciminib + golimumab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• goserelin
Scemblix (asciminib)

+

goserelin

1 interaction

Monitor/Modify Tx

asciminib + goserelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• guanfacine
Scemblix (asciminib)

+

guanfacine

1 interaction

Monitor/Modify Tx

asciminib + guanfacine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• Haemophilus b vaccine
Scemblix (asciminib)

+

Haemophilus b vaccine

1 interaction

Monitor/Modify Tx

asciminib + Haemophilus b vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• haloperidol
Scemblix (asciminib)

+

haloperidol

1 interaction

Monitor/Modify Tx

asciminib + haloperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hepatitis A vaccine
Scemblix (asciminib)

+

hepatitis A vaccine

1 interaction

Monitor/Modify Tx

asciminib + hepatitis A vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis B immune globulin
Scemblix (asciminib)

+

hepatitis B immune globulin

1 interaction

Monitor/Modify Tx

asciminib + hepatitis B immune globulin

monitor thrombosis s/sx; use lowest hepatitis B immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• hepatitis B vaccine
Scemblix (asciminib)

+

hepatitis B vaccine

1 interaction

Monitor/Modify Tx

asciminib + hepatitis B vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• histrelin
Scemblix (asciminib)

+

histrelin

1 interaction

Monitor/Modify Tx

asciminib + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hoodia
Scemblix (asciminib)

+

hoodia

1 interaction

Monitor/Modify Tx

asciminib + hoodia

monitor BP: combo may incr. risk of HTN (additive effects)

• human papillomavirus vaccine
Scemblix (asciminib)

+

human papillomavirus vaccine

1 interaction

Monitor/Modify Tx

asciminib + human papillomavirus vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydralazine
Scemblix (asciminib)

+

hydralazine

1 interaction

Monitor/Modify Tx

asciminib + hydralazine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrochlorothiazide
Scemblix (asciminib)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

asciminib + hydrochlorothiazide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• hydrocortisone
Scemblix (asciminib)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

asciminib + hydrocortisone

monitor BP: combo may incr. risk of HTN (additive effects)

• hydroxocobalamin IV
Scemblix (asciminib)

+

hydroxocobalamin IV

1 interaction

Monitor/Modify Tx

asciminib + hydroxocobalamin IV

monitor BP: combo may incr. risk of HTN (additive effects)

• hydroxyurea
Scemblix (asciminib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

asciminib + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyzine
Scemblix (asciminib)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

asciminib + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibrutinib
Scemblix (asciminib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

asciminib + ibrutinib

consider decr. ibrutinib dose; monitor BP, cardiac fxn: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, HTN, cardiotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• ibuprofen
Scemblix (asciminib)

+

ibuprofen

1 interaction

Monitor/Modify Tx

asciminib + ibuprofen

monitor BP, thrombosis s/sx; use lowest effective ibuprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• ibutilide
Scemblix (asciminib)

+

ibutilide

1 interaction

Monitor/Modify Tx

asciminib + ibutilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Scemblix (asciminib)

+

idelalisib

1 interaction

Monitor/Modify Tx

asciminib + idelalisib

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• ifosfamide
Scemblix (asciminib)

+

ifosfamide

1 interaction

Monitor/Modify Tx

asciminib + ifosfamide

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• imatinib
Scemblix (asciminib)

+

imatinib

1 interaction

Monitor/Modify Tx

asciminib + imatinib

monitor CBC, cardiac fxn: combo may incr. imatinib levels, risk of myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

• immune globulin
Scemblix (asciminib)

+

immune globulin

1 interaction

Monitor/Modify Tx

asciminib + immune globulin

monitor thrombosis s/sx; use lowest immune globulin dose, concentration and infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• indapamide
Scemblix (asciminib)

+

indapamide

1 interaction

Monitor/Modify Tx

asciminib + indapamide

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• indomethacin
Scemblix (asciminib)

+

indomethacin

1 interaction

Monitor/Modify Tx

asciminib + indomethacin

monitor BP, thrombosis s/sx; use lowest effective indomethacin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• infliximab
Scemblix (asciminib)

+

infliximab

1 interaction

Monitor/Modify Tx

asciminib + infliximab

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• influenza H5N1 vaccine
Scemblix (asciminib)

+

influenza H5N1 vaccine

1 interaction

Monitor/Modify Tx

asciminib + influenza H5N1 vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• influenza vaccine
Scemblix (asciminib)

+

influenza vaccine

1 interaction

Monitor/Modify Tx

asciminib + influenza vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Scemblix (asciminib)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

asciminib + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• interferon beta 1a
Scemblix (asciminib)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

asciminib + interferon beta 1a

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• interferon beta 1b
Scemblix (asciminib)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

asciminib + interferon beta 1b

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• interferon gamma 1b
Scemblix (asciminib)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

asciminib + interferon gamma 1b

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• iohexol
Scemblix (asciminib)

+

iohexol

1 interaction

Monitor/Modify Tx

asciminib + iohexol

if IV iohexol use, monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• iomeprol
Scemblix (asciminib)

+

iomeprol

1 interaction

Monitor/Modify Tx

asciminib + iomeprol

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• iopamidol
Scemblix (asciminib)

+

iopamidol

1 interaction

Monitor/Modify Tx

asciminib + iopamidol

if IV iopamidol use, monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• irbesartan
Scemblix (asciminib)

+

irbesartan

1 interaction

Monitor/Modify Tx

asciminib + irbesartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• irinotecan
Scemblix (asciminib)

+

irinotecan

1 interaction

Monitor/Modify Tx

asciminib + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (BCRP-mediated transport possibly inhibited)

• isoflurane
Scemblix (asciminib)

+

isoflurane

1 interaction

Monitor/Modify Tx

asciminib + isoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isradipine
Scemblix (asciminib)

+

isradipine

1 interaction

Monitor/Modify Tx

asciminib + isradipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ivabradine
Scemblix (asciminib)

+

ivabradine

1 interaction

Monitor/Modify Tx

asciminib + ivabradine

monitor HR, ECG: combo may incr. ivabradine levels, risk of bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivosidenib
Scemblix (asciminib)

+

ivosidenib

1 interaction

Monitor/Modify Tx

asciminib + ivosidenib

monitor ECG, electrolytes: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. asciminib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ixabepilone
Scemblix (asciminib)

+

ixabepilone

1 interaction

Monitor/Modify Tx

asciminib + ixabepilone

monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• Japanese encephalitis vaccine
Scemblix (asciminib)

+

Japanese encephalitis vaccine

1 interaction

Monitor/Modify Tx

asciminib + Japanese encephalitis vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ketamine
Scemblix (asciminib)

+

ketamine

1 interaction

Monitor/Modify Tx

asciminib + ketamine

monitor BP: combo may incr. risk of HTN (additive effects)

• ketoconazole
Scemblix (asciminib)

+

ketoconazole

1 interaction

Monitor/Modify Tx

asciminib + ketoconazole

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• ketoprofen
Scemblix (asciminib)

+

ketoprofen

1 interaction

Monitor/Modify Tx

asciminib + ketoprofen

monitor BP, thrombosis s/sx; use lowest effective ketoprofen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• ketorolac
Scemblix (asciminib)

+

ketorolac

1 interaction

Monitor/Modify Tx

asciminib + ketorolac

monitor BP, thrombosis s/sx; use lowest effective ketorolac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• labetalol
Scemblix (asciminib)

+

labetalol

1 interaction

Monitor/Modify Tx

asciminib + labetalol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lanreotide
Scemblix (asciminib)

+

lanreotide

1 interaction

Monitor/Modify Tx

asciminib + lanreotide

monitor BP: combo may incr. risk of HTN (additive effects)

• lapatinib
Scemblix (asciminib)

+

lapatinib

1 interaction

Monitor/Modify Tx

asciminib + lapatinib

monitor cardiac fxn, incl. ECG: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

• lazertinib
Scemblix (asciminib)

+

lazertinib

1 interaction

Monitor/Modify Tx

asciminib + lazertinib

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• leflunomide
Scemblix (asciminib)

+

leflunomide

1 interaction

Monitor/Modify Tx

asciminib + leflunomide

monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

• lemborexant
Scemblix (asciminib)

+

lemborexant

1 interaction

Monitor/Modify Tx

asciminib + lemborexant

adjust max lemborexant dose to 5 mg/day: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• lenalidomide
Scemblix (asciminib)

+

lenalidomide

1 interaction

Monitor/Modify Tx

asciminib + lenalidomide

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• lenvatinib
Scemblix (asciminib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

asciminib + lenvatinib

monitor BP, cardiac fxn, thrombosis s/sx: combo may incr. risk of HTN, cardiotoxicity, thromboembolism (additive effects)

• leuprolide
Scemblix (asciminib)

+

leuprolide

1 interaction

Monitor/Modify Tx

asciminib + leuprolide

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Scemblix (asciminib)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + levalbuterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• levofloxacin
Scemblix (asciminib)

+

levofloxacin

1 interaction

Monitor/Modify Tx

asciminib + levofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levoketoconazole
Scemblix (asciminib)

+

levoketoconazole

1 interaction

Monitor/Modify Tx

asciminib + levoketoconazole

if asciminib 200 mg bid, monitor CBC, ECG; otherwise, monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• levomilnacipran
Scemblix (asciminib)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

asciminib + levomilnacipran

monitor BP: combo may incr. risk of HTN (additive effects)

• levonorgestrel (contraceptive)
Scemblix (asciminib)

+

levonorgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + levonorgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• levonorgestrel (hormone replacement)
Scemblix (asciminib)

+

levonorgestrel (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + levonorgestrel (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• licorice
Scemblix (asciminib)

+

licorice

1 interaction

Monitor/Modify Tx

asciminib + licorice

monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects)

• linagliptin
Scemblix (asciminib)

+

linagliptin

1 interaction

Monitor/Modify Tx

asciminib + linagliptin

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• linezolid
Scemblix (asciminib)

+

linezolid

1 interaction

Monitor/Modify Tx

asciminib + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lisdexamfetamine
Scemblix (asciminib)

+

lisdexamfetamine

1 interaction

Monitor/Modify Tx

asciminib + lisdexamfetamine

monitor BP: combo may incr. risk of HTN (additive effects)

• lisinopril
Scemblix (asciminib)

+

lisinopril

1 interaction

Monitor/Modify Tx

asciminib + lisinopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lofexidine
Scemblix (asciminib)

+

lofexidine

1 interaction

Monitor/Modify Tx

asciminib + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lomitapide
Scemblix (asciminib)

+

lomitapide

1 interaction

Monitor/Modify Tx

asciminib + lomitapide

max lomitapide dose 30 mg/day: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• lopinavir/ritonavir
Scemblix (asciminib)

+

lopinavir/ ritonavir

1 interaction

Monitor/Modify Tx

asciminib + lopinavir/ ritonavir

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• lorlatinib
Scemblix (asciminib)

+

lorlatinib

1 interaction

Monitor/Modify Tx

asciminib + lorlatinib

monitor BP: combo may incr. risk of HTN (additive effects)

• losartan
Scemblix (asciminib)

+

losartan

1 interaction

Monitor/Modify Tx

asciminib + losartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• lovastatin
Scemblix (asciminib)

+

lovastatin

1 interaction

Monitor/Modify Tx

asciminib + lovastatin

monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lovotibeglogene autotemcel
Scemblix (asciminib)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

asciminib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumacaftor/ivacaftor
Scemblix (asciminib)

+

lumacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

asciminib + lumacaftor/ ivacaftor

monitor BP: combo may decr. asciminib levels, efficacy; may incr. risk of HTN (hepatic metab. induced; additive effects)

• lumateperone
Scemblix (asciminib)

+

lumateperone

1 interaction

Monitor/Modify Tx

asciminib + lumateperone

monitor ECG: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurasidone
Scemblix (asciminib)

+

lurasidone

1 interaction

Monitor/Modify Tx

asciminib + lurasidone

monitor ECG: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Scemblix (asciminib)

+

lurbinectedin

1 interaction

Monitor/Modify Tx

asciminib + lurbinectedin

monitor CBC: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• luspatercept
Scemblix (asciminib)

+

luspatercept

1 interaction

Monitor/Modify Tx

asciminib + luspatercept

monitor BP; if beta thalassemia use, monitor thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• lusutrombopag
Scemblix (asciminib)

+

lusutrombopag

1 interaction

Monitor/Modify Tx

asciminib + lusutrombopag

monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Scemblix (asciminib)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

asciminib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• macimorelin
Scemblix (asciminib)

+

macimorelin

1 interaction

Monitor/Modify Tx

asciminib + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• magnesium salicylate
Scemblix (asciminib)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

asciminib + magnesium salicylate

monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

• margetuximab
Scemblix (asciminib)

+

margetuximab

1 interaction

Monitor/Modify Tx

asciminib + margetuximab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• mavacamten
Scemblix (asciminib)

+

mavacamten

1 interaction

Monitor/Modify Tx

asciminib + mavacamten

monitor cardiac fxn, incl. LVEF: combo may incr. mavacamten levels, risk of cardiotoxicity (incl. heart failure), other adverse effects (hepatic metab. inhibited, additive effects)

• mavorixafor
Scemblix (asciminib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

asciminib + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

• meclofenamate
Scemblix (asciminib)

+

meclofenamate

1 interaction

Monitor/Modify Tx

asciminib + meclofenamate

monitor BP, thrombosis s/sx; use lowest effective meclofenamate dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• medroxyprogesterone (contraceptive)
Scemblix (asciminib)

+

medroxyprogesterone (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + medroxyprogesterone (contraceptive)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• medroxyprogesterone (hormone replacement)
Scemblix (asciminib)

+

medroxyprogesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + medroxyprogesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• mefenamic acid
Scemblix (asciminib)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

asciminib + mefenamic acid

monitor BP, thrombosis s/sx; use lowest effective mefenamic acid dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• megestrol
Scemblix (asciminib)

+

megestrol

1 interaction

Monitor/Modify Tx

asciminib + megestrol

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• meningococcal vaccine
Scemblix (asciminib)

+

meningococcal vaccine

1 interaction

Monitor/Modify Tx

asciminib + meningococcal vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• menotropins
Scemblix (asciminib)

+

menotropins

1 interaction

Monitor/Modify Tx

asciminib + menotropins

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• mercaptopurine
Scemblix (asciminib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

asciminib + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Scemblix (asciminib)

+

mesalamine

1 interaction

Monitor/Modify Tx

asciminib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Scemblix (asciminib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

asciminib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methamphetamine
Scemblix (asciminib)

+

methamphetamine

1 interaction

Monitor/Modify Tx

asciminib + methamphetamine

monitor BP: combo may incr. risk of HTN (additive effects)

• methotrexate
Scemblix (asciminib)

+

methotrexate

1 interaction

Monitor/Modify Tx

asciminib + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

• methoxy polyethylene glycol-epoetin beta
Scemblix (asciminib)

+

methoxy polyethylene glycol-epoetin beta

1 interaction

Monitor/Modify Tx

asciminib + methoxy polyethylene glycol-epoetin beta

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• methyldopa
Scemblix (asciminib)

+

methyldopa

1 interaction

Monitor/Modify Tx

asciminib + methyldopa

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• methylergonovine
Scemblix (asciminib)

+

methylergonovine

1 interaction

Monitor/Modify Tx

asciminib + methylergonovine

monitor BP: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• methylphenidate
Scemblix (asciminib)

+

methylphenidate

1 interaction

Monitor/Modify Tx

asciminib + methylphenidate

monitor BP: combo may incr. risk of HTN (additive effects)

• methylprednisolone
Scemblix (asciminib)

+

methylprednisolone

1 interaction

Monitor/Modify Tx

asciminib + methylprednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• methyltestosterone
Scemblix (asciminib)

+

methyltestosterone

1 interaction

Monitor/Modify Tx

asciminib + methyltestosterone

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• metoclopramide
Scemblix (asciminib)

+

metoclopramide

1 interaction

Monitor/Modify Tx

asciminib + metoclopramide

monitor BP: combo may incr. risk of HTN (additive effects)

• metolazone
Scemblix (asciminib)

+

metolazone

1 interaction

Monitor/Modify Tx

asciminib + metolazone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• metoprolol
Scemblix (asciminib)

+

metoprolol

1 interaction

Monitor/Modify Tx

asciminib + metoprolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• midazolam
Scemblix (asciminib)

+

midazolam

1 interaction

Monitor/Modify Tx

asciminib + midazolam

monitor resp. rate: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• mifepristone
Scemblix (asciminib)

+

mifepristone

1 interaction

Monitor/Modify Tx

asciminib + mifepristone

if asciminib 200 mg bid, monitor CBC during and x14 days after daily mifepristone use; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• milnacipran
Scemblix (asciminib)

+

milnacipran

1 interaction

Monitor/Modify Tx

asciminib + milnacipran

monitor BP: combo may incr. risk of HTN (additive effects)

• minoxidil
Scemblix (asciminib)

+

minoxidil

1 interaction

Monitor/Modify Tx

asciminib + minoxidil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• mirabegron
Scemblix (asciminib)

+

mirabegron

1 interaction

Monitor/Modify Tx

asciminib + mirabegron

monitor BP: combo may incr. risk of HTN (additive effects)

• mirdametinib
Scemblix (asciminib)

+

mirdametinib

1 interaction

Monitor/Modify Tx

asciminib + mirdametinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• mitoxantrone
Scemblix (asciminib)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

asciminib + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport possibly inhibited, additive effects)

• modafinil
Scemblix (asciminib)

+

modafinil

1 interaction

Monitor/Modify Tx

asciminib + modafinil

monitor BP: combo may incr. risk of HTN (additive effects)

• moexipril
Scemblix (asciminib)

+

moexipril

1 interaction

Monitor/Modify Tx

asciminib + moexipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• momelotinib
Scemblix (asciminib)

+

momelotinib

1 interaction

Monitor/Modify Tx

asciminib + momelotinib

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• morphine
Scemblix (asciminib)

+

morphine

1 interaction

Monitor/Modify Tx

asciminib + morphine

monitor resp. rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (P-gp-mediated transport possibly inhibited)

• moxifloxacin
Scemblix (asciminib)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

asciminib + moxifloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mycophenolate mofetil
Scemblix (asciminib)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

asciminib + mycophenolate mofetil

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mycophenolic acid
Scemblix (asciminib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

asciminib + mycophenolic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nabumetone
Scemblix (asciminib)

+

nabumetone

1 interaction

Monitor/Modify Tx

asciminib + nabumetone

monitor BP, thrombosis s/sx; use lowest effective nabumetone dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• nadolol
Scemblix (asciminib)

+

nadolol

1 interaction

Monitor/Modify Tx

asciminib + nadolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• naproxen
Scemblix (asciminib)

+

naproxen

1 interaction

Monitor/Modify Tx

asciminib + naproxen

monitor BP, thrombosis s/sx; use lowest effective naproxen dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• naratriptan
Scemblix (asciminib)

+

naratriptan

1 interaction

Monitor/Modify Tx

asciminib + naratriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• nateglinide
Scemblix (asciminib)

+

nateglinide

1 interaction

Monitor/Modify Tx

asciminib + nateglinide

monitor glucose, especially if asciminib 200 mg bid: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• naxitamab
Scemblix (asciminib)

+

naxitamab

1 interaction

Monitor/Modify Tx

asciminib + naxitamab

monitor BP: combo may incr. risk of HTN (additive effects)

• nebivolol
Scemblix (asciminib)

+

nebivolol

1 interaction

Monitor/Modify Tx

asciminib + nebivolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• necitumumab
Scemblix (asciminib)

+

necitumumab

1 interaction

Monitor/Modify Tx

asciminib + necitumumab

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• nefazodone
Scemblix (asciminib)

+

nefazodone

1 interaction

Monitor/Modify Tx

asciminib + nefazodone

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• nelfinavir
Scemblix (asciminib)

+

nelfinavir

1 interaction

Monitor/Modify Tx

asciminib + nelfinavir

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• nicardipine
Scemblix (asciminib)

+

nicardipine

1 interaction

Monitor/Modify Tx

asciminib + nicardipine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• nifedipine
Scemblix (asciminib)

+

nifedipine

1 interaction

Monitor/Modify Tx

asciminib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• nilotinib
Scemblix (asciminib)

+

nilotinib

1 interaction

Monitor/Modify Tx

asciminib + nilotinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nimodipine
Scemblix (asciminib)

+

nimodipine

1 interaction

Monitor/Modify Tx

asciminib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• nintedanib
Scemblix (asciminib)

+

nintedanib

1 interaction

Monitor/Modify Tx

asciminib + nintedanib

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• niraparib
Scemblix (asciminib)

+

niraparib

1 interaction

Monitor/Modify Tx

asciminib + niraparib

monitor BP: combo may incr. risk of HTN (additive effects)

• nisoldipine
Scemblix (asciminib)

+

nisoldipine

1 interaction

Monitor/Modify Tx

asciminib + nisoldipine

monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• norelgestromin (contraceptive)
Scemblix (asciminib)

+

norelgestromin (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + norelgestromin (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• norepinephrine
Scemblix (asciminib)

+

norepinephrine

1 interaction

Monitor/Modify Tx

asciminib + norepinephrine

monitor BP: combo may incr. risk of severe HTN (additive effects)

• norethindrone (contraceptive)
Scemblix (asciminib)

+

norethindrone (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + norethindrone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• norethindrone (hormone replacement)
Scemblix (asciminib)

+

norethindrone (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + norethindrone (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• norgestimate (contraceptive)
Scemblix (asciminib)

+

norgestimate (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + norgestimate (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• norgestrel (contraceptive)
Scemblix (asciminib)

+

norgestrel (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + norgestrel (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• obinutuzumab
Scemblix (asciminib)

+

obinutuzumab

1 interaction

Monitor/Modify Tx

asciminib + obinutuzumab

monitor BP, thrombosis s/sx: combo may incr. risk of thromboembolism, HTN, incl. hypertensive crisis (additive effects)

• olaparib
Scemblix (asciminib)

+

olaparib

1 interaction

Monitor/Modify Tx

asciminib + olaparib

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• oliceridine
Scemblix (asciminib)

+

oliceridine

1 interaction

Monitor/Modify Tx

asciminib + oliceridine

monitor resp. rate, ECG: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• olmesartan medoxomil
Scemblix (asciminib)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

asciminib + olmesartan medoxomil

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• olodaterol inhaled
Scemblix (asciminib)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + olodaterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• olsalazine
Scemblix (asciminib)

+

olsalazine

1 interaction

Monitor/Modify Tx

asciminib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ondansetron
Scemblix (asciminib)

+

ondansetron

1 interaction

Monitor/Modify Tx

asciminib + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Scemblix (asciminib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

asciminib + osilodrostat

monitor BP: combo may incr. risk of HTN (additive effects)

• osimertinib
Scemblix (asciminib)

+

osimertinib

1 interaction

Monitor/Modify Tx

asciminib + osimertinib

monitor electrolytes, cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

• ospemifene
Scemblix (asciminib)

+

ospemifene

1 interaction

Monitor/Modify Tx

asciminib + ospemifene

monitor thrombosis s/sx: combo may incr. ospemifene levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• oxaprozin
Scemblix (asciminib)

+

oxaprozin

1 interaction

Monitor/Modify Tx

asciminib + oxaprozin

monitor BP, thrombosis s/sx; use lowest effective oxaprozin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• oxymetazoline nasal
Scemblix (asciminib)

+

oxymetazoline nasal

1 interaction

Monitor/Modify Tx

asciminib + oxymetazoline nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• oxytocin
Scemblix (asciminib)

+

oxytocin

1 interaction

Monitor/Modify Tx

asciminib + oxytocin

monitor BP: combo may incr. risk of HTN, incl. life-threatening (additive effects)

• ozanimod
Scemblix (asciminib)

+

ozanimod

1 interaction

Monitor/Modify Tx

asciminib + ozanimod

monitor BP: combo may incr. risk of HTN, incl. hypertensive crisis (additive effects)

• paclitaxel
Scemblix (asciminib)

+

paclitaxel

1 interaction

Monitor/Modify Tx

asciminib + paclitaxel

if on asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• paliperidone
Scemblix (asciminib)

+

paliperidone

1 interaction

Monitor/Modify Tx

asciminib + paliperidone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Scemblix (asciminib)

+

palonosetron

1 interaction

Monitor/Modify Tx

asciminib + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Scemblix (asciminib)

+

pasireotide

1 interaction

Monitor/Modify Tx

asciminib + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pegaspargase
Scemblix (asciminib)

+

pegaspargase

1 interaction

Monitor/Modify Tx

asciminib + pegaspargase

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• pegfilgrastim (G-CSF)
Scemblix (asciminib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

asciminib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Scemblix (asciminib)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

asciminib + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Scemblix (asciminib)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

asciminib + peginterferon beta 1a

monitor CBC, cardiac fxn: combo may incr. risk of myelosuppression, cardiotoxicity (additive effects)

• pemigatinib
Scemblix (asciminib)

+

pemigatinib

1 interaction

Monitor/Modify Tx

asciminib + pemigatinib

monitor phosphate: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• perindopril
Scemblix (asciminib)

+

perindopril

1 interaction

Monitor/Modify Tx

asciminib + perindopril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pertuzumab
Scemblix (asciminib)

+

pertuzumab

1 interaction

Monitor/Modify Tx

asciminib + pertuzumab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• pexidartinib
Scemblix (asciminib)

+

pexidartinib

1 interaction

Monitor/Modify Tx

asciminib + pexidartinib

monitor BP: combo may incr. pexidartinib levels, risk of hepatotoxicity, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• phendimetrazine
Scemblix (asciminib)

+

phendimetrazine

1 interaction

Monitor/Modify Tx

asciminib + phendimetrazine

monitor BP: combo may incr. risk of HTN (additive effects)

• phenobarbital
Scemblix (asciminib)

+

phenobarbital

1 interaction

Monitor/Modify Tx

asciminib + phenobarbital

monitor ECG, resp. rate, phenobarbital levels if seizure disorder use, especially if asciminib 200 mg bid: combo may incr. phenobarbital levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. asciminib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• phenoxybenzamine
Scemblix (asciminib)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

asciminib + phenoxybenzamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phentermine
Scemblix (asciminib)

+

phentermine

1 interaction

Monitor/Modify Tx

asciminib + phentermine

monitor BP: combo may incr. risk of HTN (additive effects)

• phentolamine
Scemblix (asciminib)

+

phentolamine

1 interaction

Monitor/Modify Tx

asciminib + phentolamine

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• phenylephrine
Scemblix (asciminib)

+

phenylephrine

1 interaction

Monitor/Modify Tx

asciminib + phenylephrine

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine injection
Scemblix (asciminib)

+

phenylephrine injection

1 interaction

Monitor/Modify Tx

asciminib + phenylephrine injection

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine nasal
Scemblix (asciminib)

+

phenylephrine nasal

1 interaction

Monitor/Modify Tx

asciminib + phenylephrine nasal

monitor BP: combo may incr. risk of HTN (additive effects)

• phenylephrine ophthalmic
Scemblix (asciminib)

+

phenylephrine ophthalmic

1 interaction

Monitor/Modify Tx

asciminib + phenylephrine ophthalmic

monitor BP; HTN risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN (additive effects)

• phenylephrine rectal
Scemblix (asciminib)

+

phenylephrine rectal

1 interaction

Monitor/Modify Tx

asciminib + phenylephrine rectal

monitor BP: combo may incr. risk of HTN (additive effects)

• phenytoin
Scemblix (asciminib)

+

phenytoin

1 interaction

Monitor/Modify Tx

asciminib + phenytoin

monitor phenytoin levels, especially if asciminib 200 mg bid: combo may incr. phenytoin levels, risk of toxicity; may decr. asciminib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• pindolol
Scemblix (asciminib)

+

pindolol

1 interaction

Monitor/Modify Tx

asciminib + pindolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• pioglitazone
Scemblix (asciminib)

+

pioglitazone

1 interaction

Monitor/Modify Tx

asciminib + pioglitazone

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• piroxicam
Scemblix (asciminib)

+

piroxicam

1 interaction

Monitor/Modify Tx

asciminib + piroxicam

monitor BP, thrombosis s/sx; use lowest effective piroxicam dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• pitavastatin
Scemblix (asciminib)

+

pitavastatin

1 interaction

Monitor/Modify Tx

asciminib + pitavastatin

monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

• pneumococcal vaccine
Scemblix (asciminib)

+

pneumococcal vaccine

1 interaction

Monitor/Modify Tx

asciminib + pneumococcal vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• poliovirus vaccine
Scemblix (asciminib)

+

poliovirus vaccine

1 interaction

Monitor/Modify Tx

asciminib + poliovirus vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
Scemblix (asciminib)

+

pomalidomide

1 interaction

Monitor/Modify Tx

asciminib + pomalidomide

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• ponatinib
Scemblix (asciminib)

+

ponatinib

1 interaction

Monitor/Modify Tx

asciminib + ponatinib

monitor cardiac fxn, BP, thrombosis s/sx: combo may incr. risk of cardiotoxicity, HTN, thromboembolism (additive effects)

• ponesimod
Scemblix (asciminib)

+

ponesimod

1 interaction

Monitor/Modify Tx

asciminib + ponesimod

monitor BP: combo may incr. risk of HTN (additive effects)

• porfimer
Scemblix (asciminib)

+

porfimer

1 interaction

Monitor/Modify Tx

asciminib + porfimer

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• posaconazole
Scemblix (asciminib)

+

posaconazole

1 interaction

Monitor/Modify Tx

asciminib + posaconazole

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• pravastatin
Scemblix (asciminib)

+

pravastatin

1 interaction

Monitor/Modify Tx

asciminib + pravastatin

monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

• prazosin
Scemblix (asciminib)

+

prazosin

1 interaction

Monitor/Modify Tx

asciminib + prazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• prednisolone
Scemblix (asciminib)

+

prednisolone

1 interaction

Monitor/Modify Tx

asciminib + prednisolone

monitor BP: combo may incr. risk of HTN (additive effects)

• prednisone
Scemblix (asciminib)

+

prednisone

1 interaction

Monitor/Modify Tx

asciminib + prednisone

monitor BP: combo may incr. risk of HTN (additive effects)

• procainamide
Scemblix (asciminib)

+

procainamide

1 interaction

Monitor/Modify Tx

asciminib + procainamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• progesterone (hormone replacement)
Scemblix (asciminib)

+

progesterone (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + progesterone (hormone replacement)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• progesterone vaginal (hormone replacement)
Scemblix (asciminib)

+

progesterone vaginal (hormone replacement)

1 interaction

Monitor/Modify Tx

asciminib + progesterone vaginal (hormone replacement)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• proguanil
Scemblix (asciminib)

+

proguanil

1 interaction

Monitor/Modify Tx

asciminib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• propranolol
Scemblix (asciminib)

+

propranolol

1 interaction

Monitor/Modify Tx

asciminib + propranolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• prothrombin complex concentrate (human)
Scemblix (asciminib)

+

prothrombin complex concentrate (human)

1 interaction

Monitor/Modify Tx

asciminib + prothrombin complex concentrate (human)

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• pseudoephedrine
Scemblix (asciminib)

+

pseudoephedrine

1 interaction

Monitor/Modify Tx

asciminib + pseudoephedrine

monitor BP: combo may incr. risk of HTN (additive effects)

• pyrimethamine
Scemblix (asciminib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

asciminib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• quetiapine
Scemblix (asciminib)

+

quetiapine

1 interaction

Monitor/Modify Tx

asciminib + quetiapine

monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

• quinapril
Scemblix (asciminib)

+

quinapril

1 interaction

Monitor/Modify Tx

asciminib + quinapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• quinidine (antiarrhythmic)
Scemblix (asciminib)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

asciminib + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• quinidine (CYP2D6 inhibitor)
Scemblix (asciminib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

asciminib + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Scemblix (asciminib)

+

quinine

1 interaction

Monitor/Modify Tx

asciminib + quinine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• raloxifene
Scemblix (asciminib)

+

raloxifene

1 interaction

Monitor/Modify Tx

asciminib + raloxifene

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• ramipril
Scemblix (asciminib)

+

ramipril

1 interaction

Monitor/Modify Tx

asciminib + ramipril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• ramucirumab
Scemblix (asciminib)

+

ramucirumab

1 interaction

Monitor/Modify Tx

asciminib + ramucirumab

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• ranibizumab
Scemblix (asciminib)

+

ranibizumab

1 interaction

Monitor/Modify Tx

asciminib + ranibizumab

monitor thrombosis s/sx; risk may be lower if ocular implant use: combo may incr. risk of thromboembolism (additive effects)

• ranolazine
Scemblix (asciminib)

+

ranolazine

1 interaction

Monitor/Modify Tx

asciminib + ranolazine

monitor ECG: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (P-gp-mediated transport possibly inhibited)

• red yeast rice
Scemblix (asciminib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

asciminib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• regorafenib
Scemblix (asciminib)

+

regorafenib

1 interaction

Monitor/Modify Tx

asciminib + regorafenib

monitor BP: combo may incr. risk of HTN (additive effects)

• repaglinide
Scemblix (asciminib)

+

repaglinide

1 interaction

Monitor/Modify Tx

asciminib + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• respiratory syncytial virus vaccine
Scemblix (asciminib)

+

respiratory syncytial virus vaccine

1 interaction

Monitor/Modify Tx

asciminib + respiratory syncytial virus vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• revumenib
Scemblix (asciminib)

+

revumenib

1 interaction

Monitor/Modify Tx

asciminib + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• Rho(D) immune globulin
Scemblix (asciminib)

+

Rho(D) immune globulin

1 interaction

Monitor/Modify Tx

asciminib + Rho(D) immune globulin

monitor thrombosis s/sx; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of thromboembolism (additive effects)

• ribavirin
Scemblix (asciminib)

+

ribavirin

1 interaction

Monitor/Modify Tx

asciminib + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ribociclib
Scemblix (asciminib)

+

ribociclib

1 interaction

Monitor/Modify Tx

asciminib + ribociclib

monitor ECG, electrolytes, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• rifabutin
Scemblix (asciminib)

+

rifabutin

1 interaction

Monitor/Modify Tx

asciminib + rifabutin

monitor CBC: combo may decr. asciminib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. induced; additive effects)

• rimegepant
Scemblix (asciminib)

+

rimegepant

1 interaction

Monitor/Modify Tx

asciminib + rimegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• riociguat
Scemblix (asciminib)

+

riociguat

1 interaction

Monitor/Modify Tx

asciminib + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport possibly inhibited)

• ripretinib
Scemblix (asciminib)

+

ripretinib

1 interaction

Monitor/Modify Tx

asciminib + ripretinib

monitor BP, cardiac fxn, incl. LVEF: combo may incr. risk of HTN, cardiotoxicity (additive effects)

• ritlecitinib
Scemblix (asciminib)

+

ritlecitinib

1 interaction

Monitor/Modify Tx

asciminib + ritlecitinib

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• ritonavir
Scemblix (asciminib)

+

ritonavir

1 interaction

Monitor/Modify Tx

asciminib + ritonavir

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• rituximab
Scemblix (asciminib)

+

rituximab

1 interaction

Monitor/Modify Tx

asciminib + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rizatriptan
Scemblix (asciminib)

+

rizatriptan

1 interaction

Monitor/Modify Tx

asciminib + rizatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• romidepsin
Scemblix (asciminib)

+

romidepsin

1 interaction

Monitor/Modify Tx

asciminib + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• romiplostim
Scemblix (asciminib)

+

romiplostim

1 interaction

Monitor/Modify Tx

asciminib + romiplostim

monitor platelets, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• ropinirole
Scemblix (asciminib)

+

ropinirole

1 interaction

Monitor/Modify Tx

asciminib + ropinirole

monitor BP: combo may incr. risk of HTN (additive effects)

• rosiglitazone
Scemblix (asciminib)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

asciminib + rosiglitazone

if on asciminib 200 mg bid, monitor glucose, cardiac fxn; otherwise, monitor cardiac fxn: combo may incr. rosiglitazone levels, risk of hypoglycemia, cardiotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• rosuvastatin
Scemblix (asciminib)

+

rosuvastatin

1 interaction

Monitor/Modify Tx

asciminib + rosuvastatin

monitor CK, myopathy sx: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport possibly inhibited)

• rotigotine transdermal
Scemblix (asciminib)

+

rotigotine transdermal

1 interaction

Monitor/Modify Tx

asciminib + rotigotine transdermal

monitor BP: combo may incr. risk of HTN (additive effects)

• rucaparib
Scemblix (asciminib)

+

rucaparib

1 interaction

Monitor/Modify Tx

asciminib + rucaparib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib
Scemblix (asciminib)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

asciminib + ruxolitinib

monitor thrombosis s/sx, CBC, especially if asciminib 200 mg bid: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, thromboembolism, other adverse effects (hepatic metab. inhibited, additive effects)

• ruxolitinib topical
Scemblix (asciminib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

asciminib + ruxolitinib topical

monitor CBC, thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• salmeterol inhaled
Scemblix (asciminib)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + salmeterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• salsalate
Scemblix (asciminib)

+

salsalate

1 interaction

Monitor/Modify Tx

asciminib + salsalate

monitor thrombosis s/sx, BP w/ high-dose salsalate: combo may incr. risk of HTN, thromboembolism (additive effects)

• sargramostim (GM-CSF)
Scemblix (asciminib)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

asciminib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Scemblix (asciminib)

+

sarilumab

1 interaction

Monitor/Modify Tx

asciminib + sarilumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• satralizumab
Scemblix (asciminib)

+

satralizumab

1 interaction

Monitor/Modify Tx

asciminib + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saxagliptin
Scemblix (asciminib)

+

saxagliptin

1 interaction

Monitor/Modify Tx

asciminib + saxagliptin

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• segesterone (contraceptive)
Scemblix (asciminib)

+

segesterone (contraceptive)

1 interaction

Monitor/Modify Tx

asciminib + segesterone (contraceptive)

monitor thrombosis s/sx, especially w/ concomitant estrogen use: combo may incr. risk of thromboembolism (additive effects)

• selpercatinib
Scemblix (asciminib)

+

selpercatinib

1 interaction

Monitor/Modify Tx

asciminib + selpercatinib

monitor ECG, electrolytes, BP: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, other adverse effects (hepatic metab. inhibited, additive effects)

• selumetinib
Scemblix (asciminib)

+

selumetinib

1 interaction

Monitor/Modify Tx

asciminib + selumetinib

monitor CK, myopathy sx, cardiac fxn, incl. LVEF: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, additive effects)

• sevoflurane
Scemblix (asciminib)

+

sevoflurane

1 interaction

Monitor/Modify Tx

asciminib + sevoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• siponimod
Scemblix (asciminib)

+

siponimod

1 interaction

Monitor/Modify Tx

asciminib + siponimod

monitor BP, HR, ECG: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, HTN, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• sipuleucel-T
Scemblix (asciminib)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

asciminib + sipuleucel-T

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• sirolimus
Scemblix (asciminib)

+

sirolimus

1 interaction

Monitor/Modify Tx

asciminib + sirolimus

monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• sitagliptin
Scemblix (asciminib)

+

sitagliptin

1 interaction

Monitor/Modify Tx

asciminib + sitagliptin

monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

• smallpox/mpox vaccine, live
Scemblix (asciminib)

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

asciminib + smallpox/ mpox vaccine, live

consider vaccinating at least 4wk before or 3mo after asciminib tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• sodium tetradecyl sulfate
Scemblix (asciminib)

+

sodium tetradecyl sulfate

1 interaction

Monitor/Modify Tx

asciminib + sodium tetradecyl sulfate

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• solriamfetol
Scemblix (asciminib)

+

solriamfetol

1 interaction

Monitor/Modify Tx

asciminib + solriamfetol

monitor BP: combo may incr. risk of HTN (additive effects)

• sorafenib
Scemblix (asciminib)

+

sorafenib

1 interaction

Monitor/Modify Tx

asciminib + sorafenib

monitor BP, cardiac fxn: combo may incr. risk of HTN, cardiotoxicity (additive effects)

• sotatercept
Scemblix (asciminib)

+

sotatercept

1 interaction

Monitor/Modify Tx

asciminib + sotatercept

monitor Hgb, thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• spironolactone
Scemblix (asciminib)

+

spironolactone

1 interaction

Monitor/Modify Tx

asciminib + spironolactone

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• stiripentol
Scemblix (asciminib)

+

stiripentol

1 interaction

Monitor/Modify Tx

asciminib + stiripentol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succimer
Scemblix (asciminib)

+

succimer

1 interaction

Monitor/Modify Tx

asciminib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sufentanil
Scemblix (asciminib)

+

sufentanil

1 interaction

Monitor/Modify Tx

asciminib + sufentanil

monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• sulfasalazine
Scemblix (asciminib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

asciminib + sulfasalazine

monitor CBC: combo may incr. sulfasalazine levels, risk of myelosuppression, other adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport possibly inhibited, additive effects)

• sulindac
Scemblix (asciminib)

+

sulindac

1 interaction

Monitor/Modify Tx

asciminib + sulindac

monitor BP, thrombosis s/sx; use lowest effective sulindac dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• sumatriptan
Scemblix (asciminib)

+

sumatriptan

1 interaction

Monitor/Modify Tx

asciminib + sumatriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• sunitinib
Scemblix (asciminib)

+

sunitinib

1 interaction

Monitor/Modify Tx

asciminib + sunitinib

monitor BP, cardiac fxn; consider monitoring LVEF: combo may incr. risk of HTN, cardiotoxicity (additive effects)

• tacrolimus
Scemblix (asciminib)

+

tacrolimus

1 interaction

Monitor/Modify Tx

asciminib + tacrolimus

monitor tacrolimus levels, ECG, renal fxn, BP: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, HTN, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, additive effects)

• tadalafil
Scemblix (asciminib)

+

tadalafil

1 interaction

Monitor/Modify Tx

asciminib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• tagraxofusp
Scemblix (asciminib)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

asciminib + tagraxofusp

monitor BP: combo may incr. risk of HTN (additive effects)

• talazoparib
Scemblix (asciminib)

+

talazoparib

1 interaction

Monitor/Modify Tx

asciminib + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited)

• taletrectinib
Scemblix (asciminib)

+

taletrectinib

1 interaction

Monitor/Modify Tx

asciminib + taletrectinib

monitor ECG, electrolytes: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tamoxifen
Scemblix (asciminib)

+

tamoxifen

1 interaction

Monitor/Modify Tx

asciminib + tamoxifen

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• telavancin
Scemblix (asciminib)

+

telavancin

1 interaction

Monitor/Modify Tx

asciminib + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telmisartan
Scemblix (asciminib)

+

telmisartan

1 interaction

Monitor/Modify Tx

asciminib + telmisartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• temsirolimus
Scemblix (asciminib)

+

temsirolimus

1 interaction

Monitor/Modify Tx

asciminib + temsirolimus

monitor CBC: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• tenofovir alafenamide
Scemblix (asciminib)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

asciminib + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited, gut BCRP-mediated transport possibly inhibited)

• tenofovir disoproxil
Scemblix (asciminib)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

asciminib + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited, gut BCRP-mediated transport possibly inhibited)

• teplizumab
Scemblix (asciminib)

+

teplizumab

1 interaction

Monitor/Modify Tx

asciminib + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• terazosin
Scemblix (asciminib)

+

terazosin

1 interaction

Monitor/Modify Tx

asciminib + terazosin

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• terbutaline
Scemblix (asciminib)

+

terbutaline

1 interaction

Monitor/Modify Tx

asciminib + terbutaline

monitor BP: combo may incr. risk of HTN (additive effects)

• teriflunomide
Scemblix (asciminib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

asciminib + teriflunomide

monitor CBC, BP: combo may incr. risk of myelosuppression, HTN (additive effects)

• testosterone
Scemblix (asciminib)

+

testosterone

1 interaction

Monitor/Modify Tx

asciminib + testosterone

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• tetrabenazine
Scemblix (asciminib)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

asciminib + tetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thalidomide
Scemblix (asciminib)

+

thalidomide

1 interaction

Monitor/Modify Tx

asciminib + thalidomide

monitor CBC, thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• tick-borne encephalitis vaccine
Scemblix (asciminib)

+

tick-borne encephalitis vaccine

1 interaction

Monitor/Modify Tx

asciminib + tick-borne encephalitis vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• timolol
Scemblix (asciminib)

+

timolol

1 interaction

Monitor/Modify Tx

asciminib + timolol

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• tipranavir
Scemblix (asciminib)

+

tipranavir

1 interaction

Monitor/Modify Tx

asciminib + tipranavir

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• tivozanib
Scemblix (asciminib)

+

tivozanib

1 interaction

Monitor/Modify Tx

asciminib + tivozanib

monitor BP, cardiac fxn, thrombosis s/sx: combo may incr. risk of HTN (incl. hypertensive crisis), cardiotoxicity, thromboembolism (additive effects)

• tocilizumab
Scemblix (asciminib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

asciminib + tocilizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tofacitinib
Scemblix (asciminib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

asciminib + tofacitinib

monitor CBC, thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• tolmetin
Scemblix (asciminib)

+

tolmetin

1 interaction

Monitor/Modify Tx

asciminib + tolmetin

monitor BP, thrombosis s/sx; use lowest effective tolmetin dose, shortest effective tx duration: combo may incr. risk of HTN, thromboembolism (additive effects)

• tolvaptan
Scemblix (asciminib)

+

tolvaptan

1 interaction

Monitor/Modify Tx

asciminib + tolvaptan

consider decr. tolvaptan dose: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metab. inhibited)

• torsemide
Scemblix (asciminib)

+

torsemide

1 interaction

Monitor/Modify Tx

asciminib + torsemide

monitor renal fxn, BP, especially if asciminib 200 mg bid: combo may incr. torsemide levels, risk of nephrotoxicity, hypotension, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• trabectedin
Scemblix (asciminib)

+

trabectedin

1 interaction

Monitor/Modify Tx

asciminib + trabectedin

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• tramadol
Scemblix (asciminib)

+

tramadol

1 interaction

Monitor/Modify Tx

asciminib + tramadol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trametinib
Scemblix (asciminib)

+

trametinib

1 interaction

Monitor/Modify Tx

asciminib + trametinib

monitor BP, cardiac fxn (incl. LVEF), thrombosis s/sx, especially in combo w/ dabrafenib: combo may incr. risk of HTN, cardiotoxicity, thromboembolism (additive effects)

• trandolapril
Scemblix (asciminib)

+

trandolapril

1 interaction

Monitor/Modify Tx

asciminib + trandolapril

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• trastuzumab
Scemblix (asciminib)

+

trastuzumab

1 interaction

Monitor/Modify Tx

asciminib + trastuzumab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• tretinoin
Scemblix (asciminib)

+

tretinoin

1 interaction

Monitor/Modify Tx

asciminib + tretinoin

monitor thrombosis s/sx, especially during 1st month of tretinoin use: combo may incr. risk of thromboembolism (additive effects)

• triamcinolone
Scemblix (asciminib)

+

triamcinolone

1 interaction

Monitor/Modify Tx

asciminib + triamcinolone

monitor BP: combo may incr. risk of HTN (additive effects)

• triamterene
Scemblix (asciminib)

+

triamterene

1 interaction

Monitor/Modify Tx

asciminib + triamterene

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• triazolam
Scemblix (asciminib)

+

triazolam

1 interaction

Monitor/Modify Tx

asciminib + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• triclabendazole
Scemblix (asciminib)

+

triclabendazole

1 interaction

Monitor/Modify Tx

asciminib + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Scemblix (asciminib)

+

trifluridine

1 interaction

Monitor/Modify Tx

asciminib + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethoprim
Scemblix (asciminib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

asciminib + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• triptorelin
Scemblix (asciminib)

+

triptorelin

1 interaction

Monitor/Modify Tx

asciminib + triptorelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Scemblix (asciminib)

+

tucatinib

1 interaction

Monitor/Modify Tx

asciminib + tucatinib

if asciminib 200 mg bid, monitor CBC; otherwise, caution advised: combo may incr. asciminib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• typhoid vaccine
Scemblix (asciminib)

+

typhoid vaccine

1 interaction

Monitor/Modify Tx

asciminib + typhoid vaccine

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ubrogepant
Scemblix (asciminib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

asciminib + ubrogepant

monitor BP; limit ubrogepant dose to 50 mg, may give second 50 mg dose after 2h if needed: combo may incr. ubrogepant levels, risk of HTN, other adverse effects (hepatic metab. inhibited, P-gp-mediated transport possibly inhibited, BCRP-mediated transport possibly inhibited, additive effects)

• upadacitinib
Scemblix (asciminib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

asciminib + upadacitinib

monitor CBC, thrombosis s/sx: combo may incr. risk of myelosuppression, thromboembolism (additive effects)

• vadadustat
Scemblix (asciminib)

+

vadadustat

1 interaction

Monitor/Modify Tx

asciminib + vadadustat

monitor BP, Hgb, thrombosis s/sx; use lowest effective vadadustat dose: combo may incr. risk of HTN (incl. hypertensive crisis), thromboembolism (additive effects)

• valoctocogene roxaparvovec
Scemblix (asciminib)

+

valoctocogene roxaparvovec

1 interaction

Monitor/Modify Tx

asciminib + valoctocogene roxaparvovec

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• valproic acid
Scemblix (asciminib)

+

valproic acid

1 interaction

Monitor/Modify Tx

asciminib + valproic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valsartan
Scemblix (asciminib)

+

valsartan

1 interaction

Monitor/Modify Tx

asciminib + valsartan

monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

• vamorolone
Scemblix (asciminib)

+

vamorolone

1 interaction

Monitor/Modify Tx

asciminib + vamorolone

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• vancomycin
Scemblix (asciminib)

+

vancomycin

1 interaction

Monitor/Modify Tx

asciminib + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vardenafil
Scemblix (asciminib)

+

vardenafil

1 interaction

Monitor/Modify Tx

asciminib + vardenafil

monitor ECG: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• varicella zoster immune globulin
Scemblix (asciminib)

+

varicella zoster immune globulin

1 interaction

Monitor/Modify Tx

asciminib + varicella zoster immune globulin

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• vasopressin
Scemblix (asciminib)

+

vasopressin

1 interaction

Monitor/Modify Tx

asciminib + vasopressin

monitor BP: combo may incr. risk of HTN (additive effects)

• vemurafenib
Scemblix (asciminib)

+

vemurafenib

1 interaction

Monitor/Modify Tx

asciminib + vemurafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• venlafaxine
Scemblix (asciminib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

asciminib + venlafaxine

monitor BP: combo may incr. risk of HTN (additive effects)

• verapamil
Scemblix (asciminib)

+

verapamil

1 interaction

Monitor/Modify Tx

asciminib + verapamil

monitor BP: combo may incr. verapamil levels, risk of hypotension, bradycardia, AV block, other adverse effects; may decr. antihypertensive agent efficacy (hepatic metab. inhibited; antagonistic effects)

• vilanterol inhaled
Scemblix (asciminib)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

asciminib + vilanterol inhaled

monitor BP: combo may incr. risk of HTN (additive effects)

• viloxazine
Scemblix (asciminib)

+

viloxazine

1 interaction

Monitor/Modify Tx

asciminib + viloxazine

monitor BP: combo may incr. risk of HTN (additive effects)

• vinblastine
Scemblix (asciminib)

+

vinblastine

1 interaction

Monitor/Modify Tx

asciminib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Scemblix (asciminib)

+

vincristine

1 interaction

Monitor/Modify Tx

asciminib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Scemblix (asciminib)

+

vinorelbine

1 interaction

Monitor/Modify Tx

asciminib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• voclosporin
Scemblix (asciminib)

+

voclosporin

1 interaction

Monitor/Modify Tx

asciminib + voclosporin

monitor BP: combo may incr. risk of HTN (additive effects)

• von Willebrand factor
Scemblix (asciminib)

+

von Willebrand factor

1 interaction

Monitor/Modify Tx

asciminib + von Willebrand factor

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• voriconazole
Scemblix (asciminib)

+

voriconazole

1 interaction

Monitor/Modify Tx

asciminib + voriconazole

if asciminib 200 mg bid, monitor CBC, ECG; otherwise, monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• vorinostat
Scemblix (asciminib)

+

vorinostat

1 interaction

Monitor/Modify Tx

asciminib + vorinostat

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)

• warfarin
Scemblix (asciminib)

+

warfarin

1 interaction

Monitor/Modify Tx

asciminib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• yohimbe
Scemblix (asciminib)

+

yohimbe

1 interaction

Monitor/Modify Tx

asciminib + yohimbe

monitor BP: combo may incr. risk of HTN (additive effects)

• zanidatamab
Scemblix (asciminib)

+

zanidatamab

1 interaction

Monitor/Modify Tx

asciminib + zanidatamab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• zanubrutinib
Scemblix (asciminib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

asciminib + zanubrutinib

monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• zavegepant
Scemblix (asciminib)

+

zavegepant

1 interaction

Monitor/Modify Tx

asciminib + zavegepant

monitor BP: combo may incr. risk of HTN (additive effects)

• zenocutuzumab
Scemblix (asciminib)

+

zenocutuzumab

1 interaction

Monitor/Modify Tx

asciminib + zenocutuzumab

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• zidovudine
Scemblix (asciminib)

+

zidovudine

1 interaction

Monitor/Modify Tx

asciminib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziftomenib
Scemblix (asciminib)

+

ziftomenib

1 interaction

Monitor/Modify Tx

asciminib + ziftomenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziv-aflibercept
Scemblix (asciminib)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

asciminib + ziv-aflibercept

monitor BP, thrombosis s/sx: combo may incr. risk of HTN, thromboembolism (additive effects)

• zolmitriptan
Scemblix (asciminib)

+

zolmitriptan

1 interaction

Monitor/Modify Tx

asciminib + zolmitriptan

monitor BP: combo may incr. risk of HTN (additive effects)

• zongertinib
Scemblix (asciminib)

+

zongertinib

1 interaction

Monitor/Modify Tx

asciminib + zongertinib

monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

• zopapogene imadenovec
Scemblix (asciminib)

+

zopapogene imadenovec

1 interaction

Monitor/Modify Tx

asciminib + zopapogene imadenovec

monitor thrombosis s/sx: combo may incr. risk of thromboembolism (additive effects)